

A

- AA (Alcoholics Anonymous), 302–304
- AACP (American Association of Child and Adolescent Psychiatry), 393
- AAIDD (American Association on Intellectual and Developmental Disabilities), 396
- ABAB design, 98
- Abilify (aripiprazole), 407
- Abkhazia, 411
- Abuse, recovered memories of, 216–217
- ACA (Patient Protection and Affordable Care Act), 24, 302
- Academic achievement, 374
- Acamprosate, 304
- ACC (anterior cingulate cortex), 229
- Acceptance
 - and commitment therapy (ACT), 43, 235
 - in dialectical behavior therapy, 459
- Acculturation, 331
- Acetaminophen, 284
- Acocella, Joan, 220
- Acrophobia, 156
- ACT (acceptance and commitment therapy), 43, 235
- Acute stress disorder (ASD), 58, 202, 370, 389, 400
- Adaptive behavior, 396, 406
- Adderall, 39, 288, 376
- Addict, term, 273
- Addiction, 272–273. *See also* Caffeine, addiction to
- Additions. *See also* Copy number variations (CNVs)
- ADH (alcohol dehydrogenases), 293
- ADHD. *See* Attention-deficit/hyperactivity disorder (ADHD)
- Adler, Alfred, 19
- Adolescents
 - ADHD in, 374
 - anxiety in, 390–392
 - body dissatisfaction for, 331–332
 - bulimia nervosa in, 319
 - and cyclothymic disorder, 122
 - depression in, 385–394. *See also* Treatment for Adolescents with Depression Study (TADS)
 - eating disorder prevention for, 337
 - and lifetime prevalence rates of mood and anxiety disorders, 385
 - limited antisocial behavior, 379–380
 - personality disorders in, 437, 445
 - and Prozac 388
 - and schizophrenia, 244–245
 - smoking and negative life events for, 297
 - substance use disorder in, 292–293, 299
 - substance use prevention for, 310–311
- Adolescent-onset conduct disorder, 380
- Adoptees method, 95
- Adoption studies, 249, 375, 380, 443
- Adrenal cortex, 38
- Adrenocorticotrophic hormone, 38
- Adult antisocial personality disorder, 66
- Adulthood
 - ADHD in, 374–375
 - autism spectrum disorder in, 403
 - conduct disorder in, 380
- Adversity, childhood. *See* Childhood adversity
- Advertising, 300, 321–322
- Advocacy groups, 5
- Affect, 45. *See also* Emotion(s)
 - blunted, 242
 - ideal, 46
 - negative, 298, 439
- Affection, parental, 441
- African Americans
 - alcohol use disorders for, 274
 - antipsychotic use by, 263
 - cultural bias in assessment with, 82–83
 - culturally competent treatment of, 104–105
 - eating disorders for, 331
 - psychopathology for, 47
 - PTSD for, 202
 - schizophrenia for, 239
 - and stereotype threat, 76
 - tobacco use by, 277
 - vascular dementia for, 424
- Age and aging, 260, 330, 410–414. *See also* Late life
- Age effects, 413
- Agency for Healthcare Research and Quality, 412
- Age regression, 222
- Aggression, 40–41
 - and ADHD, 371
 - and alcohol use, 298–299
 - and bipolar disorders, 476–477
 - and conduct disorder, 377–378, 380–381
- Agitation, 426
- Agoraphobia, 66, 101, 155, 415
- Agoraphobia clinical description of, 159–160
- Agoraphobia etiology of, 175
- Agoraphobia in late life, 415
- Agoraphobia prevalence of, 156
- Agoraphobia treatments for, 101, 180
- AIDS epidemic, 340
- Air Force, 150
- Akathisia, 261
- Alabama, 480
- Alarm reaction, 72
- Alaska, 281
- Alaska Natives, 274, 277
- Alba, Jessica, 329
- Alcohol
 - and ADHD medications, 389
 - and anxiety/stress, 297
 - in cross-national use studies, 299
 - expectancies and expectations about, 298
 - long-term effects of, 276
 - and neurobiology of craving, 295
 - and nicotine use, 274
 - and paraphilic disorders, 361–364
 - reported use of, 273–274
 - short-term effects of, 275–276
 - social networks and use of, 299
 - U.S. population reporting use of, 270–273
- Alcohol abuse, 93, 101, 158, 276, 415
- Alcohol dehydrogenases (ADH), 293
- Alcohol dependence, 48, 111, 299, 304
- Alcohol myopia, 297
- Alcohol dehydrogenases (ADH), 293
- Alcoholic, term, 273
- Alcoholics anonymous (AA), 302–304
- American Association of Child and Adolescent Psychiatry (AACP), 393
- American Association on Intellectual and Developmental Disabilities (AAIDD), 396
- Alcohol use disorder, 66, 273–276
 - gender differences in, 46
 - genetic influences, 292–293
 - long-term effect, 276
 - and marital distress, 68
 - and missed workdays, 68
 - prevalence of, 274
 - and risky decision making, 296
 - short-term effects of 275–276
 - treatment of, 302–304
- ALI (American Law Institute) guidelines, 464–465
- Alleles, 30
- Alogia, 242
- Alpha level, 91. *See also* statistical significance
- Alternate-form reliability, 56. *See also* Reliability
- Alternative DSM-5-TR Model for Personality Disorders, 435, 438–440
- Alternative hypotheses, 88
- Alzheimer, Alois, 419
- Alzheimer's Association, 418
- Alzheimer's disease, 419–423
 - and caregiver support, 426–427
 - global burden of, 410
 - and informed consent, 486
 - medications for treating, 425–426
- American Association of Child and Adolescent Psychiatry (AACP), 393
- AACP (American Association of Child and Adolescent Psychiatry), 393
- Amendment I, 462
- Amendment IV, 462
- Amendment V, 462
- Amendment VI, 462
- Amendment VIII, 462
- Amendment XII, 462
- Amendment, XIV, 462
- Amendment XV, 462
- American Indians. *See* Native Americans
- American Law Institute (ALI) guidelines, 464–465
- American Legacy Foundation, 310
- American Lung Association, 279
- American Psychiatric Association (APA), 50, 58, 60, 119, 143, 150, 261, 485
- American Psychological Association Board of Trustees, 438
- Americans with Disabilities Act, 267
- America's Law Enforcement and Mental Health Project Act, 482
- Amnesia, dissociative. *See* Dissociative amnesia
- Amphetamines, 46, 287–290
- Amygdala, 35
 - and autism spectrum disorder, 406
 - and borderline personality disorder, 405
 - and conduct disorder, 381
 - emotion and reward processing, involvement in, 126–128
 - and marijuana, 282
 - neurobiological correlates, 166–167
 - and psychopathy, 447–448
 - and PTSD, 204–205
 - and rewards, valuing of, 295–296
- Anafranil (clomipramine), 196
- Analogue experiments, 107–108
- Analytical psychology, 19
- Anatomical connectivity, 36
- Androgens, 362, 365
- Anesthesia, 226
- Angel dust, 291. *See also* PCP
- Anhedonia, 115
- Animal hoarding, 190–191
- Animal studies, 168, 174, 287–288
- “Anna O.,” 17, 226

- Anorexia nervosa, 314
 clinical description of, 314–317
 physical consequences of, 317
 cognitive behavioral/emotional influences of, 326–327
 cross-cultural studies of, 330–331
 DSM-5-TR criteria for, 314, 316
 genetic influences in, 324
 neurobiological influences in, 324–326
 other eating disorders vs., 318–323
 personality influences on, 332
 nervosa prognosis, 317
 psychological treatment of, 350
 ANS. See Autonomic nervous system
- Antabuse, 305
- Antagonism, 439
- Anterior cingulate, 35, 126–128
- Anterior cingulate cortex (ACC), 127, 167, 192, 219, 229, 276, 296, 450, 453
- Anterior insula, 229
- Anticipatory pleasure, 242
- Anticonvulsants, 141, 143
- Antidepressants, 39, 141–142
 for anxiety disorders, 180–181
 for childhood disorders, 387, 389–390
 for dementia, 425–426
 for eating disorders, 325–326, 334, 336
 for major depressive disorder, 141–144
 for obsessive-compulsive and related disorders, 196
 for paraphilic disorders, 365
 for personality disorders, 457–458
 controversies, 388
 and sexual dysfunction, 350, 355
 for somatic symptom/illness anxiety disorder, 235
 and suicidality, 149
 warnings on, 102
 U.S. use of, 136
- Antihistamines, 261
- Anti-NMDA-receptor autoimmune encephalitis, 65
- Antipsychotic drugs (antipsychotics), 39, 102
 for autism spectrum disorder, 497
 for bipolar disorder, 143
 and brain structure/function, 252–253
 for dementia, 425–426
 development of, 260–261
 and dopamine theory, 251
 evaluation of, 263–264
 first-generation, 261
 right to refuse, 481
 for schizophrenia, 260–263
 for schizotypal personality disorder, 458
 second-generation, 262–263
 side effects of, 260–263
- Antiseizure medications, 102, 143
- Antisocial behavior, 379–383, 445–448
- Antisocial personality disorder (APD), 434, 445–448
 in adoptees, 95
 clinical description of, 445
- comorbidities with, 436
- conduct disorder treatments and, 384
- DSM-5 criteria for, 446
- emotions with, 46
- etiology of, 446–448
- gender differences in, 46–47
- heritability of, 441
- inter-rater reliability for, 437
- key features of, 435
- maladaptive cognitions with, 457
- prevalence of, 436
- Antisocial personality disorder (APD), psychopathy vs., 445–446
- Antithesis, 459
- Anxiety, 154
 and ADHD, 373–374
 in adolescence, 390–394
 and alcohol consumption, 296
 and attention to threat, 168–169
 and autism spectrum disorder, 403
 in childhood, 390–394
 and conduct disorder, 379
 and depression, 131
 fear vs., 154
 and LSD, 289–290
 medications to reduce, 180–181
 in older adults, 414
 and personality disorders, 436
 and personality traits, 440
 and sexual dysfunction, 352
 and somatic symptom disorders, 228, 235
- Anxiety disorders, 153–183
 anxiety and fear in, 154
 autonomic nervous system in, 37
 and binge eating disorder, 322
 and bulimia nervosa, 318
 in childhood and adolescence, 390–393
 clinical description of, 155–161, 390–392
 co-diagnoses with, 66
 comorbidity in, 161
 and culture, 162–163
 defining, 154
 and depressive disorders, 120
 in DSM-5-TR, 370
 etiology of, 170–176, 392
 and gender, 162
 international prevalence of, 62
 meta-analyses of, 111
 neuroscience approaches to, 39–40
 neurotransmitters involved in, 34
 and obsessive-compulsive related disorders, 191
 and personality disorders, 436
 and posttraumatic stress disorder, 203
 prevalence of, 93, 390
 risk factors for, 440–441
 and somatic symptom and related disorders, 222–224
 treatment of, 177–181, 392–393
- Anxiety Sensitivity Index (ASI), 175
- Anxiolytics, 180
- Anxious/fearful cluster (personality disorders), 454–456
- AOT (assisted outpatient treatment), 478
- Assisted outpatient treatment (AOT), 478
- APA. See American Psychological Association (APA)
- Apathy, 241, 417, 420
- APD. See Antisocial personality disorder (APD)
- Aphonia, 226
- ApoE ϵ 4 allele, 422
- Applied behavior analysis, 398
- Appraisal, 22
- APS (attenuated psychosis syndrome), 245–246
- Attenuated psychosis syndrome (APS), 245–246
- Archetypes, 19
- Aricept (donepezil), 425
- Aripiprazole (Abilify), 407
- Arousal. See also biological arousal; sexual arousal
 and anxiety/fear, 154
 biological, 343–344, 346–347
 and paraphilic disorders, 356, 358–359
 physiological and sexual, 352
 sexual disorders involving, 346–347
 in gender and sexuality, 342–343
- Arousal and reactivity symptoms (PTSD), 201–202, 391
- Anterior cingulate cortex (ACC), 229
- ASD. See Acute stress disorder; Autism spectrum disorder
- ASI (Anxiety Sensitivity Index), 175
- Anxiety Sensitivity Index (ASI), 175
- Asians and Asian Americans
 alcohol tolerance of, 293
 alcohol use disorders for, 274
 anxiety disorders for, 162–163
 cultural bias in assessment with, 82–83
 depressive symptoms for, 119–120
 emotion, modulating, 105
 rates of psychological disorders for, 61
 tobacco use by, 277
- Asociality, 241
- Asperger, Hans, 401
- Asperger's disorder, 59, 401
- Asphyxiophilia, 360
- Assessment, 55–57, 70–85
 behavior, directly observing, 76–77
 clinical interviews for, 70–73
 cognitive tests, 75–76
 cultural and racial bias in, 82–84
 diagnosis, 58–69
 experience sampling, 77
 intelligence test, 75–76
 neurobiological, 79–82
 neuropsychological tests, 75–76
 personality tests, 73–75
 psychological, 70–78
 reliability in, 55–56
 self-report questionnaires, 77
 stress, 72
 validity in, 56–57
- Assimilation, cultural. See Acculturation
- Assisted outpatient treatment (AOT), 478
- AOT (assisted outpatient treatment), 478
- Association studies. See Genome-wide association studies (GWAS)
- Asylums, 11–13
- Ataque de nervios*, 8, 62, 202
- Atkins, Daryl, 474–475
- Atkins v. Virginia*, 475
- Attachments, 402–403
- Attachment theory, 19
- Attachment therapies, 102
- Attention
 cognitive science view of, 43
 and delirium, 428–429
 to internal vs. social cues, 172
 joint, 401, 407
 in somatic symptom and related disorders, 230–231
 to threat, 168–169
- Attention-deficit/hyperactivity disorder (ADHD), 371–377
 in adulthood, 374–375
 and binge eating disorder, 322–323
 bipolar disorder vs., 388–389
 clinical descriptions of, 371–374
 comorbidity with, 372–373
 in DSM-5-TR, 370, 372–373
 ethnicity and prevalence of, 48
 etiology of, 375–376
 family factors in, 376
 gender differences in, 48
 genetic influences, 375
 neurobiological influences, 375
 neuroscience approaches to, 39–40
 ODD vs., 378
 prevalence of, 371–374
 prognosis of, 371–374
 psychological treatment for, 377
 sex differences, 373–374
 stimulant medications for, 376–377
 treatment of, 376–377
- Attenuated psychosis syndrome (APS), 245–246
- APS (attenuated psychosis syndrome), 245–246
- Attractiveness, 194, 335, 355, 451
- Attribution(s), 132
- Attributional style, 132, 387
- Auditory hallucinations, 46, 241
- Aurora, Colorado, 467, 477
- Australia, 259, 299, 320, 330–331
- Autism, 400–401
- Autism spectrum, 400–401
- Autism spectrum disorder (ASD), 400–407
 brief history of, 401
 clinical description of, 400–402
 social and emotional disturbances, 400–402
 communications deficits, 402
 repetitive and ritualistic acts, 402–403
 comorbidity and, 403
 in DSM-5-TR, 370
 etiology of, 404–406

- and fragile X syndrome, 397
- Temple Grandin on, 404
- history of, 401
- prevalence of, 403
- prognosis for children with, 403
- treatment of, 406–407
- Autistic aloneness, 401
- Autistic disorder, 401
- Autoimmune reactions, 65
- Autonomic nervous system (ANS), 37, 381
- ANS (autonomic nervous system), 37, 381
- Aversion therapy, 365
- Aversive feedback, 447
- Aversive parental behavior, 441
- Avoidance (avoidant behaviors), 213, 231
- Avoidance symptoms (PTSD), 201–202
- Avoidant personality disorder, 158, 454–455
 - arbitrariness, 437–438
 - comorbidities for, 437
 - defining symptoms for, 455
 - heritability of, 441
 - inter-rater reliability for, 437
 - key features of, 435
 - maladaptive cognitions with, 457
 - prevalence of, 436
 - test–retest stability for, 437
 - treatment of, 458
- Avoidant/restrictive food intake disorder, 314
- Avolition, 241, 266–267
- Awareness (of somatic symptoms), 229–231
- Axis I disorders, 59
- Axis II disorders, 59
- Axis III disorders, 59
- Axis IV disorders, 59
- Axis V disorders, 59
- B**
- BAC (blood alcohol concentration), 275
- Blood alcohol concentration (BAC), 275
- Baltimore Longitudinal Study of Aging, 413
- Bariatric surgery, 328, 330
- Basal ganglia, 253, 295
- BA therapy. *See* Behavioral activation therapy
- BDD. *See* Body dysmorphic disorder
- Beck, Aaron, 43–45, 84, 131–133, 136–139, 149
- Bedlam, term, 11
- Behavior(s). *See also specific types, e.g.,* Safety behaviors of adolescents with ADHD, 374
 - direct observation of, 76–77
 - nonobvious causes of, 20
 - short-term effects of alcohol on, 275–276
 - unconscious influences on, 20
- Behavioral activation (BA) therapy, 40, 138–140
- Behavioral assessment, 77
- Behavioral component of emotion, 45
- Behavioral couples therapy, 140
- Behavioral factors, in disorders, 170–175
- Behavioral inhibition, 167, 392
- Behavioral model, 193
- Behavioral research, 486
- Behavioral therapies/treatments. *See also* Cognitive behavioral therapy (CBT)
 - for ADHD, 376
 - for anxiety in children, 393
 - for autism spectrum disorder, 406–407
 - for dementia, 426–427
 - influences from, 40–41
 - for intellectual disability, 398–399
 - for sexual dysfunctions, 355
 - for somatic symptom and related disorders, 233–235
- Behavioral variant FTD, 423–424
- Behavioral view of exposure treatment, 177
- Behavioral weight-loss programs, 336
- Behavior genetics, 29–30
 - correlational method in, 94–95
 - of eating disorders, 324
 - on schizophrenia, 246–251
 - on substance use disorders, 292–293
- Behaviorism, 20–22
- Belgium, 62, 104
- Beliefs
 - about sexuality, 340
 - and anxiety disorders, 167–168
 - in hoarding disorder, 194
 - negative, 167–168, 172
 - in treatment of bulimia nervosa, 335–336
- Belonging, sense of, 148
- Benzodiazepines, 39, 177, 181, 276, 416
- Bethlehem (asylum), 11–12, 14–15
- BeVocal campaign, 6
- BFI-2 (Big Five Inventory-2), 75, 78, 82
- Bianchi, Ken, 221
- Biases
 - attention, 168–169
 - cognitive, 230, 457
 - confirmation, 110
 - cultural, 82–84
 - information-processing, 131
 - publication, 109, 111
 - reporting, 344, 416
- Big data approaches to cognitive science, 42
- Big Five Inventory-2 (BFI-2), 75, 78, 82
- Biggest Loser, The* (television series), 322
- Binges, 318–319
- Binge drinking, 270, 274
- Binge eating disorder, 319–323
 - cognitive behavioral views of, 327
 - DSM-5 criteria for, 319
 - medications for, 334
 - psychological treatment for, 336–337
- Bini, Lucino, 16
- Biological approach, to psychological disorders, 10, 14–16
- Biological factors, in disorders, 117, 350. *See also* Neurobiological factors
- Biological treatments, 16, 141–144, 365
- Bipolar disorders
 - and aggression, 476
 - brain structures associated with, 128
 - in childhood and adolescence, 385–388
 - clinical descriptions of, 121–124
 - and cortisol dysregulation, 128–129
 - epidemiology and consequences of, 123
 - genetic factors in, 125
 - heritability of, 15
 - lifetime prevalence rates, 93, 385
 - living conditions for people with, 22–23
 - neurobiological hypotheses of, 125
 - and neurotransmitters, 126
 - and schizophrenia, 247, 249
 - social and psychological factors in, 134–135
 - treatment of, 140–141, 143–144
- Bipolar I disorder, 115, 121–122
 - ADHD vs., 406
 - brain structures involved in, 128
 - epidemiology and consequences of, 123
 - genetic influences in, 125
 - and lithium, 143–144
 - meta-analyses of, 111
 - predictors for, 135
 - prevalence of, 93,
 - reliability data, 68
 - and reward sensitivity, 135
- Bipolar II disorder, 115, 121–123, 125
- Birth complications, schizophrenia and, 254
- Birth weight, ADHD and, 375
- Black, William, 14
- Bleuler, Eugen, 244
- Blindness, unexplained, 232
- Blood flow, sexual response and, 343
- Blood oxygenation level dependent (BOLD) signal, 79
- Blood vessels, effect of cocaine on, 289
- Blunted affect, 242
- BMI. *See* Body mass index
- Bodily cues, 167, 174, 219
- Body dissatisfaction, 299–300
- Body dysmorphic disorder (BDD)
 - clinical description of, 188–189
 - diagnosis of, 185
 - etiology of, 194
 - prevalence of and comorbidity with, 191
 - treatment of, 195–197
- Body image, 314–315, 326–328
- Body mass index (BMI), 314–315, 319, 326, 328–330
- Body Project, 337
- Body shame, 330
- Body weight, 275, 314–315, 318, 327, 330, 332, 335
- Boldness, 446
- BOLD (blood oxygenation level dependent) signal, 79
- Borderline personality disorder (BPD), 448–451
 - and childhood sexual assault, 351
 - clinical description of, 448–449
 - empirically supported treatments for, 101
 - etiology of, 449–450
 - heritability of, 441
 - inter-rater reliability for, 437
 - key features, 435
 - neurobiological factors, 450
 - prevalence of, 415
 - risk factors for, 441
 - test–retest stability for, 437
 - treatment of, 458–459
- Bowlby, John, 51
- BPD. *See* Borderline personality disorder
- Brain, 35–36
 - and ADHD, 375
 - and auditory hallucinations, 240–241
 - and autism spectrum disorder, 405–406
 - and borderline personality disorder, 450
 - and conduct disorder, 381
 - connectivity in, 253–254
 - and eating disorders, 325, 327
 - environmental factors in development of, 254–255
 - fear circuit in, 166
 - and marijuana use, 282
 - and methamphetamines, 288
 - and mood disorders, 126–128
 - and obsessive-compulsive disorders, 192
 - and PTSD, 204–205
 - reward pathways in, 293–294
 - and schizophrenia, 251–253
 - short-term effects of alcohol on, 275–276
 - size of, autism spectrum disorder and, 405–406
 - and somatic symptom-related disorders, 229–230
 - structure and function of, 252–253
 - valuing of delayed rewards in, 296–297
- Brain imaging, 79–80
- Brain networks, 36
- Brain stimulation, 80–81
- Brain on Fire* (Cahalan), 65
- Breuer, Josef, 17
- Brief psychotic disorder, 244
- British Glossary of Mental Disorders*, 58

- British Medical Research Council, 485
 Broadcasting, thought, 240
 Broca's area, 241
 Brosh, Allie, 5
 Buddhism, 371, 433–44
 Bulimia nervosa, 318–319
 binge eating disorder vs., 319, 322–323
 cognitive behavioral views of, 327–328
 cross-cultural studies of, 331
 empirically supported treatments for, 101
 genetic influences, 324
 medications for, 334
 neurobiological influences, 324–326
 personality influences on, 332
 psychological treatment for, 335–336
 Bullying, 165, 322, 378
 Buprenorphine (Suboxone), 286, 308–309
 Bupropion (Wellbutrin), 306
 Bush, Kathleen, 227
- C**
 Caffeine, 287, G-2
 Caffeine intoxication, 64
 Cahalan, Susannah, 65
 California, 7, 16, 76, 265, 278–278, 281–282, 308, 373, 421, 473, 478–479, 482
 Callous and unemotional traits, 378, 380–381
 Cambodia, 62
 Canada, 218, 259, 331
 Cannabinoid brain receptors, 282
Cannabis sativa, 280. *See also* Marijuana
 Capital punishment, 474–475
 CAR (cortisol awakening response), 125, 129
 Carbon dioxide, panic attacks and, 174
 Cardiovascular disease, 123, 350, 420
 Cardiovascular health, 426
 Caregivers, of people with dementia, 426–427
 Carlson, Elizabeth, 220
 Carpal tunnel syndrome, 226
 Carr, David, 301
 Case studies, 87–88
 Catastrophic misinterpretation, of bodily cues, 174
 Catatonia, 243
 Categorical classification, 67
 Cathartic method, 17
 CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness), 263
 CAT scan. *See* CT scan
 Caucasians. *See also* Anglo Americans; European Americans
 eating disorders for, 331
 psychopathology for, 47
 Caudate nucleus, 192
 Causality, 92
 CB1 receptors, 282
 CBSST (cognitive-behavioral social skills training), 267
 CBT. *See* Cognitive behavioral therapy
 CBT-guided self-help (CBT-gsh), 336
 CDC. *See* Centers for Disease Control and Prevention
 Celexa (citalopram), 142
Center Cannot Hold, The (Saks), 265
 Centers for Disease Control and Prevention (CDC), 286, 373, 389, 418
 Center for Nutrition Policy and Promotion, 321
 Cerebellum, 36, 405, 421
 Cerebral hemispheres, 35
 Cerletti, Ugo, 16
 Chance, 90–91
 Chantix (varenicline), 306
 Charcot, Jean-Martin, 17
 Charpentier, Paul, 261
 CHD (coronary heart disease), 276
 Childhood abuse. *See also* Childhood sexual abuse (CSA)
 and dissociative disorders, 213, 216–217, 220
 and paraphilias, 358
 and personality disorders, 441, 449–451
 Childhood adversity
 and depression, 129–130, 133–134, 386
 and personality disorders, 441, 447, 449
 Childhood disorders, 369–408. *See also under* Children
 anxiety, 390–393
 attention-deficit/hyperactivity disorder, 371–377
 autism spectrum disorder, 400–407
 bipolar disorder, 388–389
 classification and diagnosis of, 370–371
 conduct disorder, 377–385
 controversy in diagnosis/treatment of, 388–389
 depression, 385–394
 externalizing disorders, 371–385
 intellectual disability, 394–400
 internalizing disorders, 385–394
 specific learning disorder, 394–400
 Childhood onset fluency disorder (stuttering), 395
 Childhood sexual abuse (CSA), 118, 207, 216, 351, 362. *See also* Pedophilic disorder
 Children
 effects of secondhand smoke on, 277–279
 exposure to caffeine, 287
 and factitious disorder of parents, 227
 obesity in, 320–323
 Children in the Community Study, 442, 447, 449
 China, 46, 62, 104, 118, 146, 264, 299, 305, 330
 Chinese Americans, 278
 Chlorpromazine (Thorazine), 261–262, 409
 Cholesterol, 422, 424
 Cholinesterase inhibitors, 425
 Chromosomal abnormalities, 397
 Cialis (tadalafil), 355
 Cigarettes, 271, 300, 310–311. *See also* E-cigarettes
 Cigarette smoking
 ADHD and maternal, 376
 and emotion regulation, 296–297
 genetic influences in, 292–293
 and neurobiology of craving, 294–295
 prevalence and health consequences of, 277–279
 prevention of, 310–311
 in social settings, 299
 treatments for, 304–306
 in U.S. population, 271
 Ciguatera, 226
 Cirrhosis, liver, 276, 416
 CISD (critical incident stress debriefing), 208
 Citalopram (Celexa), 142
 Civil commitment, 475–484
 civil liberties, 481–483
 current insanity pleas, 467–68
 defined, 476
 deinstitutionalization, 478–479, 481–483
 duty to warn and protect, 478–479
 gun violence, mental illness in, 477–478
 insanity defense, 464–466
 least restrictive alternative, 480
 prediction of dangerousness, 477–478
 preventive detention, 476–477
 right to refuse treatment, 481
 right to treatment, 480–481
 rights of people with psychological disorders, 479–483
 Civil liberties, 481–483
 Clark, David, 168, 179
 Classical conditioning, 20–21, 41, 87, 163–164, 170, 174, 447
 Classroom management, ADHD and, 377
 “Clear and convincing evidence,” 466
 Cleckley, Hervey, 445
 Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), 263
 Clinical high-risk studies, 246
 Clinical interviews, 70–72, 78, 436
 Clinical psychologists, 24
 Clinical significance, 92
 Clomipramine (Anafranil), 196
 Close, Glenn, 5
 Clozapine (Clozaril), 262
 Cluster A personality disorders, 435, 442
 Cluster B personality disorders, 435, 442
 Cluster C personality disorders, 435, 442
 CNVs. *See* Copy number variations
 Coal gas, 150
 Cocaine, 289
 and abstinence, 307
 cravings for, 294
 drug replacements for, 308–310
 and ideal affect, 46
 marijuana as gateway drug for, 281
 positive emotion and use of, 298
 prevalence of use of, 271
 psychological treatments for use of, 306–308
 stimulant medication use and, 388–389
 young people's use of, 280
 Cocaine Anonymous, 302
 Coca plant, 289
 Codeine, 284
Code of Ethics (APA), 484
 Coercive sexual behavior, 363
 Coffee, 287
 Cognition, 22, 41–42
 Cognitive behavioral factors, in disorders, 230–231, 326–328
 Cognitive behavioral models, 192–193, 229–230
 Cognitive behavioral influences, 40–44
 behaviorism, influence on, 41–42
 cognitive behavior therapy, 43
 cognitive science, 41–42
 evaluating, 43–44
 self-esteem and narcissism in, 475
 unconscious, role of, 42–43
 Cognitive-behavioral social skills training (CBSST), 267
 Cognitive behavioral therapy (CBT), 43
 for anxiety disorders, 177–180
 Beck's cognitive therapy, 43–44
 for childhood and adolescent anxiety, 392–393
 for childhood and adolescent depression, 387–390
 for drug use disorder, 306–310
 for eating disorders, 334–337
 CBT-guided self-help, 336
 for hoarding disorder, 198–199
 internet-based, 208
 for obsessive-compulsive disorder, 193–194
 for schizophrenia, 266–267
 for somatic symptom and related disorders, 233–235
 Cognitive behavioral treatments, 365, 458
 Cognitive biases, 43, 230
 Cognitive distortions, 266, 335, 435
 Cognitive distraction, 297–298
 Cognitive factors, in disorders, 167–169, 172, 174–175
 Cognitive functioning, 281, 396, 411, 422
 Cognitive models, 193–194
 Cognitive processing therapy, 101, 207
 Cognitive reserve, 422
 Cognitive restructuring, 43, 137
 Cognitive science, 41–42
 Cognitive theories, 131–133
 Cognitive therapy (CT)
 for bipolar disorder, 140–141
 for depression, 137–139
 Internet-based, 138

- for major depressive disorder, 137–139
 - for obsessive-compulsive disorder, 197
 - for personality disorders, 457
 - for PTSD, 207
 - for somatic symptom and related disorders, 233
 - and suicidality, 149
 - Cognitive training, 423, 427
 - Cognitive treatments, 399
 - Cognitive view of exposure treatment, 178
 - Cohort effects, 413, 416
 - Collective unconscious, 19
 - College degree, alcohol use disorders among people with, 274
 - College students, 275, 303. *See also* Young adults
 - Collyer brothers, 190
 - Colombia, 61–62, 104
 - Colorado, 281–283, 467
 - Combined specifier, ADHD, 372–373
 - Comfort food, 322
 - Commitment, 475–476. *See also* Civil commitment; Criminal commitment
 - “The Common Rule,” 485–486
 - Communication deficits, 401–402
 - Communication disorders, 370, 395
 - Communication training, 354. *See also* functional communication training (FCT)
 - Community-based prevention programs, 150, 383
 - Community treatment, 481
 - Comorbidity, 64. *See also specific disorders*
 - Competency to stand trial, 469–472
 - Complex PTSD, 202
 - Complex regional pain syndrome, 225
 - Compulsions, 71, 185–186. *See also* Obsessive compulsive disorder (OCD)
 - defined, 187
 - foci, 188
 - Computer-assisted instruction (intellectual disability), 399
 - Computerized training programs, 427
 - Concerta, 376
 - Concordance, 94
 - Conditioned response (CR), 20. *See also* Classical conditioning
 - Conditioned stimulus (CS), 20. *See also* Classical conditioning
 - Conditioning
 - classical, 20–21, 41, 87, 163–165, 170, 174, 203
 - fear, 164–165
 - interoceptive, 174
 - operant, 21, 40–41, 164, 171, 203, 398
 - in social anxiety disorder, 171
 - for specific phobias, 170–171
 - two-factor model of, 164–165
 - Conduct disorder, 377–384
 - and ADHD, 372–373
 - and antisocial personality disorder, 445
 - and binge eating disorder, 322–323
 - and bulimia nervosa, 319
 - comorbidity with and course of, 379–380
 - clinical description of, 378–379
 - etiology of, 380–382
 - and posttraumatic stress disorder, 202
 - prevalence of, 380
 - prevention of, 383–384
 - prognosis for children with, 380
 - treatment of, 382–384
 - Conduct Problems Prevention Research Group (CPRG), 384
 - Confidentiality, 487
 - Confirmation bias, 110
 - Confounds, 92
 - Connectivity, 36, 253–254
 - Constitution, U.S., 463
 - Construct validity, 58–59, 79, G-2
 - Consummatory pleasure, 250, G-3
 - Contamination, fear of, 194
 - Content validity, 56. *See also* Validity
 - Contingency management therapy, 307, 309
 - Contrast avoidance model, 175
 - Control, perceived lack of, 168
 - Control groups, 88, 96, 102–103
 - Controlled drinking, 304
 - Conversion, term, 226
 - Conversion disorder
 - clinical description of, 225–228
 - diagnosis of, 223
 - etiology of, 231–232
 - perspectives on, 232
 - influences on, 232
 - treatment of, 235
 - Coping, 205–206
 - Coping Cat, 392–393
 - Copy number variations (CNVs), 31, 125, 249–250
 - Coronary heart disease (CHD), 276
 - Corporate success, psychopathy and, 446
 - Correlates, 93–94
 - Correlation, 90
 - Correlational method, 88–95, 107
 - behavior genetics research with, 94–95
 - epidemiologic research with, 93–94
 - measuring correlation, 90
 - problems of causality in, 92
 - and statistical/clinical significance, 90–92
 - Correlation coefficient, 90–91
 - Corticotropin-releasing factor (CRF), 38
 - Cortisol, 38, 125, 164
 - Cortisol awakening response (CAR), 129
 - Cortisol dysregulation, 128–129
 - Cosmetic surgery, 411
 - Competency to stand trial, 469–472
 - Couples therapy, 48, 101, 140, 303, 354
 - CPA (cyproterone acetate), 365
 - CPRG (Conduct Problems Prevention Research Group), 384
 - CR. *See* Conditioned response
 - Crack, 289
 - Cravings, 294–295, 325
 - Creating Hysteria* (Acocella), 220
 - Creativity, mood disorders and, 123–124
 - CRF (corticotropin-releasing factor), 38
 - Crime, mental illness and, 464
 - Criminal commitment, 463–469
 - defined, 463
 - and insanity defense, 464
 - landmark cases and laws, 464–66
 - Criterion validity. *See* Validity
 - Critical incident stress debriefing (CISD), 208
 - Criticism, body image and, 326
 - Cross-cultural studies (eating disorders), 330–331
 - Cross-fostering, 95
 - Cross-gender behavior, 342
 - Cross-national studies (substance use), 299
 - Cross-sectional design, 92
 - Crystal meth, 288
 - CS. *See* Conditioned stimulus
 - CSA. *See* Childhood sexual abuse
 - CT. *See* Cognitive therapy
 - CT (CAT) scan, 65, 224
 - Cultural bias, 82–84
 - Cultural competence, 104
 - Cultural concepts of distress, 62–63
 - Cultural influences
 - in anxiety disorders, 162–163
 - in body dysmorphic disorder, 189
 - in conversion disorder, 232
 - in expressed emotion, 258
 - in internalizing/externalizing behaviors, 388
 - in obsessive-compulsive disorder, 370–371
 - in personality disorders, 435
 - in posttraumatic stress disorder, 202
 - in sexual dysfunction, 346, 352
 - in treatment outcome studies, 105
 - Culture. *See also* Ethnicity
 - and alcohol consumption, 299–300
 - and DSM classifications, 60–63
 - and gender differences in sexuality, 342
 - and sexual norms, 340–344
 - Cushing syndrome, 128
 - Cyclothymic disorder (cyclothymia), 122–23
 - CYP2A6 gene, 293
 - Cyproterone acetate (CPA, Gyrostat), 365
 - Cytokines, 38, 129
- D**
- Dadas, Albert, 218
 - Dahmer, Jeffrey, 468
 - Daily report cards (DRCs), 377
 - Daily thought monitoring, 138
 - Danes, Clare, 404
 - Dangerousness, 476–480
 - Danish Civil Registration System, 247
 - Dapoxetine, 355
 - DARE programs, 102
 - Dark Ages, 10–11
 - Dark Knight, The*, 467
 - Darwin, Charles, 224
 - DAS (Dysfunctional Attitudes Scale), 131–132
 - DAT1 gene, 293, 371
 - Daytop Village, 307
 - DBT. *See* Dialectical behavior therapy
 - Death, 317–319
 - Decentered perspective, 139
 - Decision-making,
 - methamphetamine use and, 289
 - Declaration of Helsinki, 485
 - Deep brain stimulation, 199
 - Defense mechanisms, 18
 - Defining symptoms
 - agoraphobia, 160
 - anorexia nervosa, 315
 - antisocial personality disorder, 445
 - attention-deficit/hyperactivity disorder, 372
 - autism spectrum disorder, 403
 - avoidant personality disorder, 456
 - binge eating disorder, 322
 - body dysmorphic disorder, 189
 - borderline personality disorder, 449
 - bulimia nervosa, 318
 - conduct disorder, 378
 - conversion disorder, 225
 - cyclothymic disorder, 122
 - delayed ejaculation, 348
 - delirium, 429
 - dementia, 418
 - dependent personality disorder, 454
 - depersonalization/derealization disorder, 214
 - dissociative amnesia, 215
 - dissociative identity disorder, 217
 - erectile disorder, 346
 - exhibitionistic disorder, 360
 - factitious disorder, 227
 - female orgasmic disorder, 348
 - female sexual interest/arousal disorder, 346
 - frotteuristic disorder, 360
 - gambling disorder, 272
 - general personality disorder, 435
 - generalized anxiety disorder, 160
 - genito-pelvic pain/penetration disorder, 349
 - histrionic personality disorder, 444
 - hoarding disorder, 190
 - illness anxiety disorder, 224
 - major depressive disorder, 116
 - male hypoactive sexual desire disorder, 346

- manic/hypomanic episodes, 121
mild cognitive impairment, 418
narcissistic personality disorder, 452
obsessive-compulsive disorder, 186
obsessive-compulsive personality disorder, 456
panic disorder, 159
paranoid personality disorder, 442
pedophilic disorder, 358
persistent depressive disorder, 117
posttraumatic stress disorder, 201
premature ejaculation, 348
schizoid personality disorder, 442
schizophrenia, 239
schizotypal personality disorder, 443
separation anxiety disorder, 391
sexual masochism disorder, 361
sexual sadism disorder, 361
social anxiety disorder, 158
somatic symptom disorder, 224
specific phobias, 157
substance use disorder, 271
voyeuristic disorder, 359
Deinstitutionalization, 13, 481–483
Delayed ejaculation, 348
Delayed ejaculation disorder, 348
Delayed rewards, value of
 immediate vs., 295–296
Deletions, 31
Delirium, 228–431
 and activity, 429
Delirium tremens (DTs), 273
Delusions
 and dementia, 417–418
 in schizophrenia, 239–240
 in schizotypal personality disorder, 443
 violence linked to, 476
Delusional disorders, 245
Dementia, 417–428
 and Alzheimer's disease, 419–422
 defined, 417, G-3
 delirium vs., 429
 frontotemporal, 423–424
 Huntington's disease, 425
 with Lewy bodies, 424–425
 prevalence of, 419
 treatment of, 425–427
 vascular, 424
Dementia praecox, 58, 244
Dementia with Lewy bodies (DLB), 424–425
Dendritic spines, 252–253
Denial, 18
Denmark, 247, 330
De novo mutations, 31
Dependent personality disorder, 454, 457
 in Alternative DSM-5-TR model, 438
 inter-rater reliability for, 437
 key features of, 435
 prevalence of, 436
Dependent variables, 95
Depersonalization, 159, 213–214
Depersonalization/derealization disorder, 213–214
Depo-Provera
 (medroxyprogesterone), 365
Depression. *See also* Major depressive disorder (MDD)
 and ADHD, 373–374
 in adolescence and childhood, 385–393
 and Alzheimer's disease, 420
 analogue experiments with, 107
 and anorexia nervosa, 317
 and anxiety/anxiety disorders, 130, 161
 in bipolar disorder, 134–135
 and borderline personality disorder, 448
 and bulimia nervosa, 318
 and cardiovascular disease, 120
 clinical description, 466
 co-diagnoses with, 58–59
 cognitive therapy for, 43
 comorbidities, 386
 and conduct disorder, 378–379
 cultural differences in, 117–120
 and dementia, 417, 423
 electroconvulsive therapy for, 16, 142–143
 emotions with, 45
 empirically supported treatments for, 101
 etiology of, 386–387
 gender differences in, 46, 117–118
 heritability of, 15
 neural regions associated with, 115
 and neuroticism, 167
 and neurotransmitter levels, 125–126
 and obsessive-compulsive related disorders, 192
 in older adults, 414
 and personality disorders, 436
 and personality traits, 439
 placebo effect for treatments of, 103
 prevalence, 385
 psychological factors on, 130–133
 psychological treatment of, 137–140
 with psychotic features, 476
 and sexual dysfunction, 352
 social factors on, 129–130
 and somatic symptom disorders, 229, 235
 and suicide, 147
 transcranial magnetic stimulation for, 143
 treatment of, 387–390
Depressive disorders
 clinical descriptions of, 115–117
 epidemiology and consequences of, 118–120
 medications for, 141–142
 and somatic symptom and related disorders, 222–223
Depressive symptoms, older adults with, 416
Derailment, 243
Derealization, 159, 212–213. *See also* Depersonalization/derealization disorder
Detachment, 439
Detoxification, 302, 306
Developmental coordination disorder, 395
Developmental factors
 (schizophrenia), 258–259
Developmental psychopathology, 370
Deviant peers, affiliation with, 382
Dhat syndrome, 62
Diagnosis(-es), 55–69
 of children, 388–389
 correlational studies with, 88–89
 cultural considerations in, 60–63
 with DSM-5-TR, 58–68
 general criticisms of, 68–69
 history of, 58–59
 importance of, 55
 multiaxial, 58–59
 number of, 63–66
 organizing, by cause, 59–60
 of public figures, 485
 reliability in, 55–56
 U.S. lifetime prevalence rates for, 93
 validity in, 56–57
Diagnostic and Statistical Manual of Mental Disorders (DSM), 58, 60–61, 64. *See also specific disorders*
Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR), 60–70, G-3
 criticisms of, 63–68
 definitions of psychological disorders in, 6
 diagnostic criteria of, 244–245. *See also specific disorders*
 ethnic and cultural considerations with, 60–63
 organization of diagnoses, 59–60
Diagnostic and Statistical Manual of Mental Disorders (DSM-II), 58–60, 64, 67, 218, 389, 401
Diagnostic and Statistical Manual of Mental Disorders (DSM-III), 58–59, 64, 67, 218, 401
Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R), 58, 64
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 58–59, 62, 64, 93, 111, 401
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), 58–59, 62, 64, 117, 223, 228, 401, 438
Dialectics, 459
Dialectical behavior therapy (DBT), 95–96, 149, 459
DID. *See* Dissociative identity disorder
Dieting, 328
Dimensional diagnostic system, 67
Directed masturbation, 355
Directionality problem, 92
Direct observation, 76–77
Disability, 7–8. *See also* Intellectual disability
Disconnection syndrome, 253
Disinhibition, 299, 439
Disorganized behavior, 243–244
Disorganized speech, 239, 242–243
Disorganized symptoms, 239, 242–244
Disorientation, 420
Displacement, 18
Disruptive, impulse control, and conduct disorders, 61, 370
Disruptive mood dysregulation disorder (DMDD), 115, 388
Dissemination, 105
Dissociation, 205–207, 212–213
Dissociative amnesia, 212, 214–217
Dissociative disorders, 212–222
 clinical descriptions of, 212–218
 depersonalization/derealization disorder, 213–214
 diagnoses of, 212
 dissociative amnesia, 214–217
 dissociative identity disorder, 217–218
 epidemiology of, 218
 etiology of, 219–221
 and memory, 216–217
 treatment of, 222
Dissociative fugue. *See* Fugue subtype
Dissociative identity disorder (DID), 217–221
 and childhood sexual assault, 351
 clinical description of, 217–218
 diagnosis of, 223
 epidemiology of, 218
 etiology of, 219–221
 and insanity defense, 473
 living conditions for people with, 22–23
 treatment of, 222
Dissociative identity disorder-oriented therapy, 102
Distraction, alcohol/nicotine and, 297
Distress
 cultural concepts of, 62–63
 cultural differences in expressing, 162–163
 marital, 140, 160
 over somatic symptoms, 229–230
 personal, 7
 from phobias, 7
 relationship, 48, 101, 345
Disulfiram (Antabuse), 304
Dix, Dorothea, 12–13
Dizygotic (DZ) twins, 95. *See also* Twin studies
DLB (dementia with Lewy bodies), 424–425
DMDD. *See* Disruptive mood dysregulation disorder
DNA, 28
Dodge, Kenneth, 381
Donaldson, Kenneth, 480–481
Donepezil (Aricept), 425
Dopamine, 34
 and ADHD, 375
 and alcohol, 276
 and amphetamines, 288
 and cocaine, 289
 and eating disorders, 325–326
 and methamphetamine use, 288–289
 and mood disorders, 125–126

- and schizophrenia, 250–251
and substance use disorder, 293
Dopamine theory, 251
Dorsal striatum, 325
Dorsolateral prefrontal cortex, 126–127
Double-blind procedures, 103
Down syndrome (trisomy 21), 387
Dramatic/erratic cluster (personality disorders), 444–453
DRCs (daily report cards), 377
DRD2 gene, 249
DRD4 gene, 375
DRD5 gene, 375
Dreams, dementia with Lewy bodies and, 424
Drink, measuring one, 275–276
Driving, 276, 292
Drugs. *See also* Medication(s)
and ADHD medications, 388–389
patients' understanding of, 486
prevalence of use, 270–271
Drug abuse, 93, 102, 415
Drug courts, 308
Drug Enforcement Agency, 309
Drug use disorders, 284–291, 306–310. *See also* Substance use disorders
DSM. *See Diagnostic and Statistical Manual of Mental Disorders*
DSM-5 Committee on Personality and Personality Disorders, 438
DTs (delirium tremens), 273
Dunham, Lena, 191
Dunst, Kirsten, 117
Durham test, 464–465
Durham v. United States, 465
Duty to warn and protect, 479
Dyscalculia, 395
Dysfunction, 6–8
Dysfunctional Attitudes Scale (DAS), 131–132
Dyslexia, 394–395
Dysthymia, 93. *See also* Persistent depressive disorder
DZ (dizygotic) twins, 95. *See also* Twin studies
- E**
Early ejaculation. *See* Premature ejaculation
Early infantile autism, 401
Early-intervention programs, 398
East Asian cultures, 46, 83
Eating disorders, 313–338. *See also* Obesity
anorexia nervosa, 314–317
binge eating disorder, 319–323
bulimia nervosa, 318–319
and childhood sexual assault, 351
clinical descriptions of, 314–323
cognitive behavioral factors in, 326–328
etiology of, 324–333
families of individuals with, 332–333
genetic influences, 324
meta-analyses of, 111
neurobiological influences, 324–326
and obesity, 320–322
and personality, 332
preventive interventions for, 337
sociocultural influences, 328–332
treatment of, 334–337
Eating Disorders Inventory, 315–316
eBodyProject, 337
Echolalia, 402
E-cigarettes (electronic cigarettes), 279–280, 305–306
Ecological momentary assessment (EMA), 77–78, 327
Ecstasy, 271, 289–291
ECT. *See* Electroconvulsive therapy
Education, 5, 274
EE. *See* Expressed emotion
Effect, law of, 21
Effective connectivity, 36
Effectiveness, 105
Effectiveness studies, 105
Effect size (meta-analysis), 111
Efficacy, 105
Ego, 18
Eighth Amendment, 474
EKG (electrocardiogram), 81
Elder abuse, 411
Electrocardiogram (EKG), 81
Electroconvulsive therapy (ECT), 16, 141–143
Electrodermal responding, 81
Electronic cigarettes (e-cigarettes), 279–280, 305–306
Eli Lilly, 263
EMA. *See* Ecological momentary assessment
EMDR (eye movement desensitization and reprocessing), 207
Emergency commitment, 476
Emotion(s)
of anxiety and fear, 157
and autism spectrum disorder, 402, 406
and generalized anxiety disorder, 175
and mood disorders, 126–128
and psychopathology, 45–46
and psychopathy, 445–447
regulation of, 204, 207, 289, 296–298, 362, 388, 411, 434, 459
Emotional attachment, hoarding disorder and, 195
Emotional disturbances, ASD and, 400–402
Emotional intimacy, 411
Emotional overinvolvement, 256–258
Empathy, 448
Empirically supported treatments (ESTs), 100, 105, 110
Employment, 267
Encephalitis, 398
England, 11, 15, 330, 335. *See also* Great Britain; United Kingdom
Entorhinal cortex, 421
Environmental tobacco smoke (ETS), 278
Environment and environmental factors. *See also* Sociocultural factors
in ADHD, 375–376
in autism spectrum disorder, 405
in brain development, 254–255
and intellectual disability, 398
nonshared, 29
and obesity, 321
in personality disorders, 441
shared, 28
in substance use disorders, 293
Epidemiological studies, 322
Epidemiology, 93
Epigenetics, 32
Epilepsy, 16
Episodic disorders, 116
Erectile disorder, 345–346
Erectile dysfunction, 347, 352
Erectile problems, for older adults, 414
ERP. *See* Exposure and response prevention
Eskimos, 46
ESTs. *See* Empirically supported treatments
Estradiol, 350
Ethical issues, 482–487. *See also* Legal issues
confidentiality, 487
informed consent, 486
privileged communication, 487
and restraints on research, 484–486
Ethnicity
and alcohol use disorders, 274
and dementia, 419
and eating disorders, 331–332
and mental health treatment, 263–264
and psychopathology, 47
and schizophrenia, 256
and tobacco use, 277
and treatment outcome studies, 105
Etiology, 59
ETS (environmental tobacco smoke), 278
Eugenics, 15–16
Europe, 11–12, 16, 25, 62, 111, 218, 311, 411
European Americans, 83, 258, 278. *See also* Anglo Americans; Whites
Excess, sexual behavior in, 340
Executive functioning, 259, 374
Exelon (rivastigmine), 425
Exercise, 419, 422
Exhaustion, 72
Exhibitionistic disorder, 357, 359–360
Exorcism, 10
Expectancies, about alcohol and drug effects, 295–296
Experience component of emotion, 45
Experiments, 88, 95–98
analogue, 106–108
experimental design, basic features of, 95–96
correlational studies vs., 88–89
external validity in, 96
internal validity in, 96
single-case, 96–98
treatment outcome research, 10–10
Experimental effect, 96
Explicit memory, 221
Exposure, 196
Exposure and response prevention (ERP), 196
for body dysmorphic disorder, 197
for bulimia nervosa, 336–337
with children, 393
for hoarding disorder, 198–199
Internet-based, 197
for OCD, 196–197
Exposure hierarchy, 177–178, 206
Exposure treatment (exposure therapy), 177–180, 206–208
Expressed emotion (EE), 130, 256–258, 265
Expression domain, 242
Expressive component of emotion, 196
Expressive-experiential therapies, 102
Externalizing behavior problems, 48, 370
Externalizing disorders, 32, 64, 66, 370–371, 439. *See also* Attention-deficit/hyperactivity disorder; Conduct disorder
External validity, 96
Extinction, 25, 165, 167, 169, 177, 179
Extrapyramidal side effects, 261–262
Eye movements, of children with ASD, 401–402
Eye movement desensitization and reprocessing (EMDR), 207
- F**
Facilitated communication, 102
Factitious disorder, 223
Factitious disorder imposed on another, 227
Fact magazine, 485
Factor analysis, 272
Familial high-risk studies, 248, 247–248
Families' reports, protection based on, 478–471
Family-based therapy (FBT), 334
Family CBT, 393
Family checkup (FCU) treatment, 382
Family-focused treatment (FFT), 49
Family interventions (conduct disorder), 382–383
Family method, 94
Family psychoeducation, 101, 266–267, 393
Family-related factors, in disorders, 256–258, 376
Family studies of autism spectrum disorder, 405
of schizophrenia, 247–248, 257–259
of schizotypal personality disorder, 443–444
Family support, 5

- Family therapy, 48
 for anorexia nervosa, 334–335
 for bulimia nervosa, 336
 for hoarding disorder, 198–199
 for schizophrenia, 264, 266
 for somatic symptom and related disorders, 235
- FAS (fetal alcohol syndrome), 276
- Fast Track, 384
- FBT (family-based therapy), 334
- FCU (family checkup) treatment, 382
- FDA. *See* Food and Drug Administration
- Fear(s), 154. *See also* Phobia(s)
 acquisition of, 165
 in anorexia nervosa, 314, 326, 329
 anxiety vs., 154, 388
 of contamination, 186
 of impending illness, 231
- Fear circuit, 166
- Fear conditioning (anxiety disorders), 164–165
- Fearlessness, in psychopathy, 447
- Fear-of-fear hypothesis, 175
- Fear response, extinction of, 177
- Feeding and eating disorders, 370
- Female orgasmic disorder, 345, 347–348, 352, 354–355
- Female sexual interest/arousal disorder, 346–347
- Fentanyl, 284–286
- Fetal alcohol syndrome (FAS), 276
- Fetishistic disorder, 357
- fetlife.com, 357
- FFT. *See* Family-focused treatment
- Fifty Shades of Gray* (James), 357
- Fight-or-flight reaction, 154
- Finland, 293
- First-degree relatives, 94
- First-generation antipsychotics, 261
5HTTLPR gene, 381
- Five-factor model, 439
- Flashbacks, 290
- Flight of ideas, 121
- Flint, Michigan, 398
- Florida Supreme Court, 475
- Fluoxetine (Prozac), 39, 66, 119, 141, 334, 336, 387–388
- fMRI gene, 397
- fMRI. *See* Functional magnetic resonance imaging
- Food, 313, 320–322
- Food additives, 375
- Food and Drug Administration (FDA), 81, 142–143, 196, 199, 206, 278–279, 301, 309, 311, 321, 355, 377, 388
- Food phobias, 97
- Forced medication, 472
- Forensic hospitals, 13, 463, 467–468, 471
- Foreseeable victims, protection for, 479
- Formal commitment, 475–478
- Formal thought disorder, 242
- Fragile X syndrome, 397
- France, 16, 62, 104, 118, 218, 226, 235, 255, 299
- Freud, Sigmund, 17–20, 42, 216, 226
- Friends' Asylum, 12
- Frontal cortex, 36, 125, 241, 252, 282, 289, 375, 406, 421
- Frontal lobes, 16, 375
- Fronto-striatal circuits, 192
- Frontotemporal dementia (FTD), 423–424
- Frotteuristic disorder, 357, 360
- Fugue subtype, 212, 215
- Functional connectivity, 36
- Functional magnetic resonance imaging (fMRI), 36, 79–80, 204, 230, 252, 254, 276, 282, 288, 295–296, 325, 402, 406, 453
- Fusiform gyrus, 402
- G**
- GABA. *See* Gamma-aminobutyric acid
- GABA receptors, 276
- GAD. *See* Generalized anxiety disorder
- Galen, 10
- Galton, Francis, 15
- Gambling disorder, 272–273
- Gamma-aminobutyric acid (GABA), 34, 164, 276
- GAS (general adaptation syndrome), 72
- Gassner, Johann, 17
- Gateway drug, marijuana as, 281
- Gauguin, Paul, 331
- GBMI. *See* Guilty but mentally ill
- Genain quadruplets, 248
- Gender
 and ADHD, 374
 and alcohol consumption, 274
 and alcohol use disorders, 274
 and anxiety/anxiety disorders, 162, 390
 and body dysmorphic disorder, 191
 and depression, 117–118
 and eating disorders, 317, 322
 and hoarding disorder, 190
 and ideal body weight, 328–330
 and marijuana use, 280
 and methamphetamine use, 288
 and obsessive-compulsive disorder, 191
 and ODD/conduct disorder, 378
 and opioid use, 285–286
 and paraphilic disorders, 357–358
 and psychopathology, 46–47
 and PTSD, 202
 and rape, 363
 and rumination, 133
 and schizophrenia, 260
 and sexual dysfunction, 344–345
 and sexuality, 342–343
 and suicide, 146
 and tobacco use, 277
- Gender dysphoria, 340, 342
- Gender identity, 342
- Genes, 27–31, 250
- Gene–environment interactions, 31–32, 95, 134, 292, 380, 382, 386
- Gene expression, 28
- General adaptation syndrome (GAS), 72
- General anxiety, 393
- Generalized anxiety disorder (GAD), 160
- in adolescents, 385
- clinical description of, 160
- empirically supported treatments for, 101
- etiology of, 175–76
- in late life, 415
- prevalence of, 93, 385
- psychological treatment of, 180
- General paresis, 14–15
- General personality disorder, 435
- Genetics, 15–16
- Genetic influences
 in ADHD, 375
 in antisocial personality disorder, 447
 in anxiety disorders, 166, 392
 in autism spectrum disorder, 405
 in borderline personality disorder, 450–451
 in conduct disorder, 380–381
 in depression during childhood and adolescence, 386–387
 in eating disorders, 324
 in intellectual disability, 397
 in mood disorders, 125
 in obesity, 321
 in personality disorders, 440–441
 of psychopathy, 27–33
 in schizophrenia, 247–251
 in substance use disorders, 292–293
- Genito–pelvic pain/penetration disorder, 345, 349, 355
- Genome-wide association studies (GWAS), 31
 of Alzheimer's disease, 422
 of autism spectrum disorder, 405
 of eating disorders, 324
 of mood disorders, 125
 of schizophrenia, 249–250
 of substance use disorders, 293
- Genotype, 29
- Germany, 62, 104, 300
- Germ theory of disease, 15
- Ghost sickness, 63
- Glenn, John, 411
- Global attributions, 132
- Glove anesthesia, 226
- Glutamate, 251–252
- Goals, pursuit of, 447–448
- Golden Gate Bridge, 150
- Goldwater, Barry, 485
- "Goldwater Rule," 485
- Gone with the Wind* (film), 363
- Go/no-go task, 295
- Google, 39, 42
- Grandin, Temple, 404
- Grandiose delusions, 240
- Gray matter, 35, 276
- Great Britain, 267. *See also* England; United Kingdom
- Greenland, 162
- Grief, unresolved, 49
- Grief counseling, 102
- Group therapy, 393, 458
- Guided imagery, 216
- Guided self-change, 304
- Guided self-help CBT, 336
- Guidelines for Translating and Adapting Tests* (ITC), 82
- Guilty but mentally ill (GBMI), 464, 468
- Gum, nicotine, 306
- Gun ownership, suicide rates and, 147
- GWAS. *See* Genome-wide association studies
- H**
- Haldol (haloperidol), 262
- Hall, Freddie Lee, 475
- Hallucinations, 240–241, 274, 420
- Hallucinogens, 271, 280, 289–290
- Hallucinogen persisting perception disorder, 290
- Haloperidol (Haldol), 262
- Halstead–Reitan battery, 76
- Harmful therapies, 102
- Hartford Retreat, 12
- Harvard School of Public Health, 300
- Hashish, 280
- HCR-20 (Historical-Clinical-Risk Management-20), 477
- Head Start program, 383
- Health anxiety, 229
- Health care system interventions, 233
- Health warnings, on cigarette packages, 311
- Healthy Weight intervention, 337
- Heart rate, antisocial behavior and, 381–382
- Henry VIII, 11
- Here's the Deal* (Mandel), 186
- Heritability, 28, 88, 95. *See also* Genetic factors
- Heroin, 284
 effects of, 284
 and ideal affect, 46
 marijuana as gateway drug for, 281
 in medications, 285
 prevalence of addition to, 295
 prevalence of use of, 271
 treatment for use of, 307
- Heterogeneous, term, 247
- High-risk method, 92
- High school education, alcohol use disorders among people with, 274
- Hikikomori*, 63
- Hillside strangler, 221
- Hinckley, John, Jr., 465–466
- Hinshaw, Stephen, 3–4
- "Hippie crack," 291
- Hippocampus
 and anxiety disorders, 167
 function of, 35
 and marijuana use, 282
 and methamphetamine use, 288
 and mood disorders, 127
 and neurocognitive disorders, 421
 and PTSD, 204–205
 and schizophrenia, 253
- Hippocrates, 10
- Hispanic Americans. *See also* Latinos
 alcohol use disorders for, 274
 eating disorders for, 331
 psychological disorders in, 47
 tobacco use by, 277
- Historical-Clinical-Risk Management-20 (HCR-20), 47
- Histrionic personality disorder, 444

- HIV (human immunodeficiency virus), 186–187
- Hoarders* (television series), 198
- Hoarding disorder
clinical description of, 189–191
diagnosis of, 185
etiology of, 194–195
prevalence and comorbidity of, 191
psychological treatment of, 198–199
in television shows, 22
- Holliday, Tess, 314
- Holmes, James, 467
- Holy Trinity Hospital (Salisbury, England), 11
- Homelessness, 4, 23, 190, 481
- Homosexuality, 340–344
- Hong Kong, 330–331
- Hopelessness, 148, 387, 390
- Hopelessness theory, 132–133
- Hospitalization, delirium and, 430
- Housing, 4
- HPA (hypothalamic–pituitary–adrenal) axis, 38, 118, 167, 251, 253–254, 322, 387
- Hydrocodone, 284–286
- Hydromorphone, 286
- Hyperactive, term, 371
- Hyperactive-impulsive specifier, ADHD, 372
- Hyperbole and a Half, 5
- Hypertension, 67, 88, 305, 320, 423, 426,
- Hypnosis, 17, 216, 218, 220–222, 235
- Hypochondriasis, term, 223
- Hypomania, 122, 124
- Hypothalamic–pituitary–adrenal axis. *See* HPA axis
- Hypothalamus, 35, 324–325
- Hypotheses, 87, 110
- Hysteria, 16, 232
- I**
- Iatrogenic, term, 220
- Icarus Project, 5
- ICD (International Classification of Diseases), 58
- “Ice,” 288
- Id, 18
- Idaho, 468
- Ideal affect, 46
- Ideal body, 328–330
- Ideas of reference, 240, 443
- IED (intermittent explosive disorder), 378
- IEP (individualized education program), 397
- Illicit drug use. *See* Substance abuse
- Illicit substance dependence, 111
- Illness anxiety disorder
fear of impending, 231
panic disorder and, 165
- Illness anxiety disorder, 66, 223
clinical description of, 225
diagnosis of, 223
etiology of, 228–229
treatment of, 233–235
- Illusions, 443
- Imaginal exposure, 41, 207
- Immediate rewards, value of delayed vs., 295–296
- Immune system, 38, 398
- Impairment, paraphilic disorders and, 357
- Implicit memory, 42, 221
- Impulsivity, 362, 445, 448
- Inattentive specifier, ADHD, 372
- Incarceration, insanity plea and, 464, 468
- Incentive-sensitization theory, 294, 325
- Incest, 358–359
- Incidence, 93
- Independent variables, 95
- Index case (proband), 94
- India, 46, 61–62, 299, 330, 478
- Individualized education program (IEP), 397
- Individual psychology, 19
- Infants, 167, 401
- Infantile autism, 401
- Infectious diseases, 398
- Inferofrontal gyrus, 295
- Informal commitment, 476
- Information-processing biases, 131
- Informed consent, 486
- Inhalants, 271. 291
- Inhibition, behavioral, 167, 340
- Inpatient hospital treatment (alcohol use disorder), 302
- Insanity
and capital punishment, 474–475
as legal concept/term, 463
psychological disorder vs., 467
- Insanity defense, 464–470, 473, 482
- Insanity Defense Reform Act, 464–466
- Insertion, thought, 240
- Insomnia, 262, 416, 422
- Institute of Medicine, 282, 389
- Insulin coma therapy, 16
- Intellectual ability, 205
- Intellectual activities, engagement in, 422–423
- Intellectual disability, 394–399
and autism spectrum disorder, 403
capital punishment for people with, 496–498
diagnosis and assessment of, 474–475
in DSM-5-TR, 370
etiology of, 397
treatment of, 398–399
- Intelligence quotient (IQ), 29
and autism spectrum disorder, 403
and conduct disorder, 381
and intellectual disability, 396–399
and schizophrenia, 258–259
- Intelligence tests (IQ tests), 75–76, 78
- Intermittent explosive disorder (IED), 378
- Intermittent reinforcement, 21
- Internal consistency reliability, 56.
See also Reliability
- Internal cues, attention to, 172
- Internalizing behavior problems, 370
- Internalizing disorders, 32. *See also*
Anxiety disorders; Depression
and ADHD, 373
age of onset, 385
and conduct disorder, 378–379
conduct disorder treatments and, 384
defined, 370
diagnosis of, 66
- Internal validity, 96. *See also*
Validity
- International Classification of Diseases (ICD), 58
- International List of Causes of Death, 58
- International Statistical Classification of Diseases, Injuries, and Causes of Death, 58
- International Test Commission, 82
- Internet-based CBT, 178, 197, 208, 235
- Internet-based cognitive therapy, 138
- Internet-based ERP, 197
- Internet gaming disorder, 272–273
- Interoceptive conditioning, 174
- Interpersonal deficits, 443
- Interpersonal difficulties,
depression and, 129–130
- Interpersonal factors, in the role of stress, 47–50
- Interpersonal fear disorder, 62
- Interpersonal therapy (IPT), 47, 137, 141, 336
- Interpretation, 17
- Inter-rater reliability, 55, 67, 72, 436. *See also* Reliability
- Interviews, 70–73
assessing stress, 72
clinical, 70–73, 78, 218, 436
motivational interviewing, 303, 305
structured, 70–72
unstructured clinical, 436
- Intravenous drug use, 286
- Intrusion symptoms (PTSD), 201–202
- Inuit, 162–163
- Invalidation, 450
- In vivo exposure, 178
- Involuntary hospitalization, 479
- Involuntary nervous system. *See* Autonomic nervous system
- IPT. *See* Interpersonal therapy
- IQ. *See* Intelligence quotient
- IQ tests. *See* Intelligence tests
- Irresistible impulse, 465
- Israel, 104, 150
- Italy, 62, 104
- J**
- Jackson v. Indiana*, 470
- Jails, 13, 482
- Jamison, Kay Redfield, 122–124
- Japan, 61–63, 104, 162, 189, 218, 330–331
- Japanese earthquake of 2011, 205
- Jeans, Robert, 211–212
- Johnson, Samuel, 187
- Johnson, Virginia, 342
- Joint attention, 401, 406–407
- Jones, Michael, 465–466
- Judicial commitment, 476
- Jung, Carl, 17, 19
- K**
- K2, 280
- Kanner, Leo, 401
- Kansas, 468
- Karlton, Lawrence, 482
- Kayak-angst, 162–163
- Kellogg’s Corn Flakes, 340
- Kelly, Horace, 474
- Ketamine, 251, 290
- Khyâl cap*, 62
- Kinsey, Alfred, 344
- Knightley, Keira, 395
- Kohut, Heinz, 452
- Kraepelin, Emil, 58, 244
- Kuzmich, Heather, 401
- Kyle, Chris, 467
- L**
- La Bicêtre, 12
- Laborit, Henri, 261
- Lady Gaga, 331
- Lanugo, 317
- Late life, 406–432
delirium in, 428–431
dementia in, 417–428
myths about, 410–411
problems experienced in, 412
psychological disorders in, 413–417
study of aging, research methods in, 412–414
- Latin America, 162, 419
- Latinos. *See also* Hispanic Americans
anxiety disorders for, 162
culturally competent treatment of, 104–105
culturally relevant syndromes for, 62
depressive symptoms for, 119
modified CBT, 105
- Laughing gas, 291
- Law of effect, 21
- LDL cholesterol, 424
- Lead, 375, 398
- Learning, 171, 447
- Learning disorders, 370, 394–400
- Least restrictive alternative, 480
- Lebanon, 62, 104
- LEDS (Life Events and Difficulties Schedule), 72
- Legal issues, 462–488
capital punishment, 474–475
civil commitment, 475–483
competency to stand trial, 469–473
criminal commitment, 463–469
deinstitutionalization, 481–483
ethical dilemmas, 484–487
insanity defense, 464–468
with paraphilic disorders, 366
prediction of dangerousness, 476–479
preventive detention, 476–479
recovered memories of abuse, 216–217
rights of people with psychological disorders, 479–483
smoking bans, 304–306

Legalization of marijuana, 282–283
 Levitra (vardenafil), 355
 Lewy bodies, dementia with, 424–425
 Life-course-persistent antisocial behavior, 379–381
 Life events
 and anxiety disorders, 168
 and depression, 133–134, 141–142
 and depression in childhood/adolescence, 386–387
 and perceived lack of control, 168
 Life Events and Difficulties Schedule (LEDS), 72–73, 78
 Lifestyle treatments, for dementia, 426–427
 Lifestyle variables, in Alzheimer's disease, 424
 Liking, wanting and, 294–295, 325
 Limited prosocial emotions, conduct disorder, 378
 Lincoln, Abraham, 149
 Linehan, Marsha, 450, 459
 Liposuction, 328
 Lithium, 143–144
 Little Albert, 21, 170
 Littlefield, Chad, 467
 Lobotomy, 16
 Locus coeruleus, 167, 173, 204
 Loneliness, in late life, 411
 Longitudinal design, 92, 413
 Long-term memory, 417
 Loose associations (derailment), 243
 Lopez, Steve, 243
 Lortab, 284
 Lovaas, Ivar, 406
 Lovato, Demi, 5–6, 121
 Low positive emotion differentiation, 327
 Low sex drive, 346
 LSD (lysergic acid diethylamide), 290
 Lunacy trials, 11
 Lunatics Tower, 12
 Lungs, effects of marijuana on, 282
 Luria–Nebraska battery, 76, 78
 Lysergic acid diethylamide (LSD), 290

M

MacArthur Violence Risk Assessment Study, 476
 Magnetic resonance imaging (MRI), 79, 405
 Maine, 279, 281–282
 Maintenance doses, 261
 Major depressive disorder (MDD), 116. *See also* Depression
 age of onset for, 119
 antidepressants for, 141–144
 and anxiety, 131
 brain structures involved in, 128
 and childhood sexual assault, 351
 in children and adolescents, 386
 cognitive theories for, 131–132
 cognitive therapy for, 137–139
 and cortisol dysregulation, 128–129
 and dissociative identity disorder, 218
 electroconvulsive therapy for, 142–143
 epidemiology and consequences of, 142–143
 and generalized anxiety disorder, 175
 genetic influences in, 125
 interpersonal therapy for, 137
 in late life, 415
 meta-analyses of, 111
 neurobiological hypotheses about, 125
 and posttraumatic stress disorder, 202
 prevalence of, 93
 and schizophrenia, 248
 test–retest stability for, 437
 Maladaptive cognitions, 457
 Male hypoactive sexual desire disorder, 345–346
 Malinger, 223, 227
 Maltreatment, antisocial behavior and, 380–381
 Mammals, weight gain by non-human, 321
 Mandel, Howie, 186
 Mania, 121. *See also* Bipolar disorders
 in bipolar disorders, 121
 brain structures involved in, 127
 in children, 388–389
 in DSM-II vs. DSM-5-TR, 60
 neurotransmitters involved in, 34
 predictors of, 135
 Manic-depressive psychosis, 58
 MAOA gene, 381
 MAO-A gene, 447
 MAOIs. *See* Monoamine oxidase inhibitors
 Marijuana, 280–283
 in cross-national studies, 299
 effects of, 281–283
 expectancies and expectations about, 298–299
 as gateway drug, 281
 genetic factors and use of, 293
 legalization of, 282–283
 prevalence of use of, 280–281
 and schizophrenia, 254
 stimulant medication use and, 388–389
 treatment for use of, 307
 U.S. population reporting use of, 271
 young people's use of, 280
 Marijuana Anonymous, 302
 Marital distress, 69, 169
 Marital therapy. *See* Couples therapy
 Mark of Shame, *The* (Hinshaw), 4
 Mask of Sanity, *The* (Cleckley), 445
 Massachusetts, 279, 281–282
 Mass hysteria, 232
 Masters, William H., 342
 Masturbation, 340, 343, 359
 Matrix treatment, 308
 Maturity, adolescence-limited antisocial behavior and, 379
 MBCT. *See* Mindfulness-based cognitive therapy
 MCI. *See* Mild cognitive impairment

MDD. *See* Major depressive disorder
 MDMA (methylenedioxy-methamphetamine), 290
 Meanness, 446
 Means restriction, 150
 Media, 300, 329, 446
 Medial prefrontal cortex, 166
 Media reports, of suicide, 147
 Medication(s)
 for ADHD, 376–377
 for alcohol use disorder, 304
 antipsychotic medication, 261
 for anxiety, 180–181
 for autism spectrum disorder, 407
 for bipolar disorders, 143–144
 black box warnings with, 388
 for childhood and adolescent depression, 387, 389–390
 for childhood disorders, 388–389
 and competency to stand trial, 472
 and delirium, 430
 for dementia, 425–426
 for depressive disorders, 141–142
 for drug use disorders, 308–310
 for eating disorders, 334
 for elderly people, 412, 416
 forced, 472, 481
 illicit prescription, 285–286
 memory loss due to, 215–216
 for mood disorders, 141
 mood-stabilizing, 143–144
 nicotine replacement, 305–306
 for obsessive-compulsive related disorders, 196
 and panic attacks, 174
 for paraphilic disorders, 366
 for personality disorders, 457
 and polypharmacy, 412
 for posttraumatic stress disorder, 206
 prescription pain medication, 286
 for rapists, 363
 right to refuse, 481
 for schizophrenia, 260–263
 and sexual dysfunction, 350, 355
 and smoking cessation, 305–306
 Medication compliance, assisted outpatient treatment for, 478
 Medicines and Healthcare Products Regulatory Agency (MHRA), 388
 Meditation, mindfulness, 178
 Medroxyprogesterone (MPA, Depo-Provera), 365
 Megan's Law, 366
 Melatonin, 119
 Memantine (Namenda), 425
 Memory(-ies)-
 and bulimia nervosa, 328
 and DID, 221
 explicit, 221
 implicit, 221
 and norepinephrine, 216
 procedural, 215
 and PTSD, 205
 recovered, 216–217
 Memory aids, 427

Memory loss, 276
 Meningitis, 398
 Meningococcal meningitis, 398
 “Mental disease or defect,” 464–466
 Mental disorder, defined, 6
 Mental enfeeblement, 244
 Mental health courts, 483
 Mental health evaluations, 4
 Mental health professions, 24–25
 Mental hospitals, 12
 Mental illness. *See* Psychological disorders
 Mentalization therapy, 459
 Mentally Ill Offender Treatment and Crime Reduction Act, 482
 Menthol cigarettes, 278, 300
 Mercury, 389
 Mesmer, Franz Anton, 16–17
 Mesmerism, 17
 Meta-analysis, 110–111
 Metabolism, 275, 291–292
 Metabolites, 325
 Meta-cognitive skills, 427
 Methadone, 286, 307–309
 Methamphetamine (meth), 288, 308
 Methamphetamine Treatment Project, 308
 Methylene-dioxymethamphetamine (MDMA), 290
 Methylphenidate, 376
 Mexican Americans, 258
 Mexico, 61–62, 104, 264, 282
 Meyer, Victor, 196
 MHRA (Medicines and Healthcare Products Regulatory Agency), 388
 Middle East, 62
 Migration, 255–256
 Mild cognitive impairment (MCI), 418–419
 Military service, 201
 Mind, structure of, 18
 Mind Freedom International, 5
 Mindfulness-based cognitive therapy (MBCT), 43, 138–139
 Mindfulness meditation, 178
 Minnesota Multiphasic Personality Inventory (MMPI, MMPI-2), 73–75, 82
 Miss Scott, 227
 MMPI. *See* Minnesota Multiphasic Personality Inventory
 MMR vaccine, 389
 M'Naghten, Daniel, 465
 M'Naghten rule, 465
 Mobile crisis units, 482
 Modeling, 20–21
 Model penal code, 465
 Moderation in drinking, 305
 Molecular genetics, 30–31, 249–251
 Molecular genetics research, 30, 125, 247, 249–251, 257
 Molly, 290
 Monahan, John, 477–478
 Monitoring the Future Survey, 283
 Moniz, Egas, 16
 Monoamine oxidase inhibitors (MAOIs), 141

- Monozygotic (MZ) twins, 95. *See also* Twin studies
- Montana, 468
- Mood
- defined, 45
 - and delirium, 429
 - and PTSD, 200–201
- Mood disorders, 114–152
- and alcohol use disorder, 275–276
 - and binge eating disorder, 322
 - bipolar, 121–124, 140–141, 143
 - clinical descriptions of, 115–116, 121–122
 - defined, 114
 - depression, 115–120, 130–133, 137–140
 - epidemiology and consequences of, 117–120, 123–130
 - etiology of, 124–135
 - international prevalence of, 62
 - medications for, 141–144
 - and personality disorders, 435
 - prevalence of, 93
 - and somatic symptom and related disorders, 224
 - and suicide, 144–150
 - treatment of, 136–144
- Mood-stabilizing medications, 143–144
- Moral awareness, 381
- Moral treatment, 12–13
- Morphine, 286
- Motivation, enhancing, 365
- Motivational interventions, 303
- Motivational interviewing, 305, 307
- Motivation and pleasure domain, 242
- Motor disorders, 370, 395
- Mowrer's two-factor model, 164–165
- MPA (medroxyprogesterone), 365
- MRI. *See* Magnetic resonance imaging
- MST. *See* Multisystemic treatment
- Multiaxial classification system, 58
- Multimodal Treatment of Children with ADHD (MTA) study, 376, 377, 389
- Multiracial individuals, alcohol use disorders among, 274
- Multisystemic treatment (MST), 383–385
- Munchausen syndrome by proxy, 227
- MZ (monozygotic) twins, 95. *See also* Twin studies
- N**
- Naloxone, 309
- Naltrexone, 304, 309–310
- Namenda (memantine), 425
- NAPLS (North American Prodrome Longitudinal Study), 259
- Narcissism, adaptive, 451–452
- Narcissistic personality disorder, 451–453, G-7
- etiology of, 452
 - heritability of, 441
 - inter-rater reliability for, 437
 - key features of, 435
- maladaptive cognitions with, 457
 - prevalence of, 436
 - risk factors for, 441
- Narcissus, 453
- Narcotics Anonymous, 302
- Nathaniel, 243
- National Alliance on Mental Illness, 5
- National Association of Social Workers, 150
- National Cancer Institute, 310
- National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 485
- National Comorbidity Survey–Replication (NCS–R) study, 93, 155, 415
- National Head Start Impact study, 383
- National Institute of Aging, 418
- National Institute of Mental Health (NIMH), 66, 102, 104, 110, 486
- National Institute on Alcohol Abuse and Alcoholism (NIAAA), 276
- National Institutes of Health (NIH), 109–110, 278, 310
- National Sheriffs Association, 13
- National Survey on Drug Use and Health, 5
- Native Americans
- alcohol use disorders among, 274
 - cultural bias in assessment with, 84
 - cultural competence with, 105
 - cultural concepts of distress, 63–64
 - tobacco use by, 277
- NAVIGATE treatment, 267
- NCS–R study. *See* National Comorbidity Survey–Replication study
- Neal, Shannon, 145
- Neal, Steven, 145
- Negative affectivity, 439
- Negative beliefs, 168, 172
- Negative cognitions, 200–201, 352
- Negative emotions, 138, 295–297, 326–327
- Negative emotionality, 298
- Negative mood, eating and, 326–327
- Negative reinforcement, 21, G-7
- Negative self-perceptions, of older adults, 412
- Negative symptoms, 241–242
- Negative thoughts, challenging, 139
- Negative triad, 131
- Nervous system
- autonomic, 37, 381
 - parasympathetic, 37
 - sympathetic, 37
- Netherlands, 62, 104, 330, 453
- Neurobiological assessment, 79–81
- brain imaging, 79–80
 - brain stimulation, 80–81
- psychophysiological assessment, 81
- Neurobiological influences
- in ADHD, 375
 - in anxiety disorders, 166–167
 - in autism spectrum disorder, 405–406
 - in borderline personality disorder, 450
 - in conduct disorder, 381
 - in eating disorders, 324–326
 - in mood disorders, 125
 - in panic disorder, 173
 - in paraphilic disorders, 362
 - in posttraumatic stress disorder, 204–205
 - in somatic symptom disorders, 229–230
 - in substance use disorders, 293–295
 - in suicide, 147
- Neuroendocrine system, 36, 38
- Neurofibrillary tangles, 420–421
- Neuroleptics, 260. *See also* Antipsychotic drugs (antipsychotics)
- Neurons, 34–35, 252–254, 421–424
- Neuropsychological influences (conduct disorder), 381
- Neuropsychiatric symptoms, with dementia, 417
- Neuropsychological tests, 76, 252
- Neuroscience influences (psychopathology), 34–40
- autonomic nervous system, 37
 - conversion disorder in, 232
 - evaluating, 39–40
 - immune system in, 38
 - neuroendocrine system in, 36, 38
 - and neurons/neurotransmitters, 34–35
 - and structure/function of brain, 35–36
 - treatment approaches, 39
- Neuroticism, 131, 164, 167, 230
- Neurotransmitters, 34–35
- in anxiety disorders, 34, 166–167
 - in depression, 125–126
 - in eating disorders, 324–326
 - in mood disorders, 125–126
 - in schizophrenia, 251–253
- Neutral predictable unpredictable (NPU) threat task, 165
- Nevada, 281–282
- New Zealand, 104, 133, 258, 281, 379, 477
- NGRI. *See* Not guilty by reason of insanity
- NIAAA (National Institute on Alcohol Abuse and Alcoholism), 276
- Nicotine, 277, 279. *See also* Cigarette smoking
- and ADHD, 375–376
 - and alcohol use, 473–474
 - metabolism of, 293
 - and negative emotion, 297
 - tension/stress and consumption of, 297
- Nicotine patches, 306
- Nicotine replacement therapy (NRT), 305–306
- Nigeria, 61–62, 104
- NIH. *See* National Institutes of Health
- NIMH. *See* National Institute of Mental Health
- Nitrous oxide, 291
- NMDA (N-methyl-D-aspartate acid), 65, 251
- Nolen-Hoeksema, Susan, 133
- Noncompliance, 370, 372
- Nonconsenting others, paraphilic disorders and, 357, 359, 360, 362
- Nonepileptic seizure disorder, 226
- Nonshared (unique) environment, 28
- Nonsuicidal self-injury (NSSI), 145–146, 201
- Norepinephrine, 34
- and anxiety disorders, 167, 173
 - and memory, 216
 - and mood disorders, 125–126
- Norms, 8, 340
- North American Prodrome Longitudinal Study (NAPLS), 259
- North Carolina, 274, 373
- Northern Ireland, 202
- Northwestern-UCLA Youth Emotion Project, 386
- Norway, 299
- Not guilty by reason of insanity (NGRI), 465–467
- No-treatment control group, 103
- Not So Subtle Art of Being a Fat Girl, The* (Holliday), 314
- NPU (neutral predictable unpredictable) threat task, 165
- NSSI. *See* Nonsuicidal self-injury
- Nucleus accumbens, 287, 294, 375
- Nuremberg Code, 485
- Nuremberg Trials, 485
- Nuthkavihak*, 46
- O**
- Obese, term, 319
- Obesity, 319–323, 328–330
- Objectification theory, 330
- Obsessions, 20–21, 186–188
- Obsessive-compulsive disorder (OCD)
- and anorexia nervosa, 317
 - anxiety disorders and, 155, 161
 - behavioral treatment for, 39
 - and body dysmorphic disorder, 188–189
 - in children, 387, 391–392
 - classification of, 59–60
 - clinical description of, 186–188
 - and deep brain stimulation, 199
 - diagnosis of, 185
 - empirically supported treatments for, 101
 - etiology of, 192–194
 - obsessive-compulsive personality disorder vs., 455–456
 - prevalence of and comorbidity with, 191
 - psychological treatment of, 195–196
 - in SCID, 71
 - television shows on, 22

- Obsessive-compulsive personality disorder, 455–456
 heritability of, 441
 inter-rater reliability for, 437
 key features of, 185, 435
 maladaptive cognitions with, 457
 prevalence of, 457
 test–retest stability for, 437
- Obsessive-compulsive-related disorders, 184–210
 clinical descriptions of, 185–191
 comorbidity with, 191
 diagnoses of, 185
 epidemiology of, 185
 etiology of, 192–195
 prevalence of, 191
 treatment of, 195–199
- Occipital lobe, 35–36
- OCD. *See* Obsessive-compulsive disorder
- O'Connor v. Donaldson, 480
- ODD. *See* Oppositional defiant disorder
- Odd/eccentric cluster (personality disorders), 435, 442–444
- Odyssey House, 307
- Olanzapine (Zyprexa), 439, 141, 143, 262, 263
- Older adults. *See* Age and aging; Late life
- Olsen, Mary-Kate, 336
- Online social interactions, 373
- Operant conditioning, 21–22, 41, 164, 171, 203, 235, 376, 398, 406
- Operation Desert Storm, 204
- Opioid antagonists, 308
- Opioids, 285–287
 effects of, 286–287
 prevalence of use, 285–286
 substitutes, 308
 withdrawal from, 306
- Opium, 284
- Oppositional defiant disorder (ODD), 66, 377–379, 388
- Orbitofrontal cortex, 192
- Oregon, 279, 281–282
- Organizational abilities, 194
- Orgasmic disorders, 345, 347–348, 355
- Orgasm phase (sexual response cycle), 344
- Other hallucinogen use disorder, 290
- Outcome research. *See* Treatment outcome research
- Outpatient treatment, assisted, 478
- Overweight, 315
- Oxycodone, 284
- OxyContin, 284–286
- Oxymorphone, 286
- P**
- Pain, somatic symptom disorders and, 223, 229, 235
- Pain medications, misuse of, 271
- Panetti, Scott, 474
- Panic, 101, 414
- Panic attacks
 analogue studies of, 107
 cognitive factors in, 174
 defined, 159
 depersonalization in, 214
- Panic disorder, 63, 155
 and anorexia nervosa, 317
 clinical description of, 155, 159
 emotions with, 45
 etiology of, 173–175
 prevalence of, 93
 psychological treatment of, 179–180
- Paracelsus, 11
- Paranoid personality disorder, 434, 442
 in Alternative DSM-5-TR model, 438–440
 comorbidities for, 438
 inter-rater reliability for, 437
 key features of, 435
 prevalence of, 436
- Paraphilic disorders, 356–366
 clinical descriptions, 356–361
 defined, 356
 in DSM-5-TR, 357
 etiology of, 361–364
 treatment for, 364–366
- Parasympathetic nervous system, 387
- Parental affection, 441
- Parental monitoring, 41, 382
- Parental rejection, 32
- Parents and parenting
 and ADHD, 376
 and antisocial personality disorder, 469
 and autism spectrum disorder, 447
 and borderline personality disorder, 449–450
 and childhood anxiety, 392
 and conduct disorder, 383
 and eating disorders, 332–333
 and narcissistic personality disorder, 452
 and personality disorders, 441
- Parent–child relationships, 20, 384
- Parent management training (PMT), 382–383
- Parent training, 377
- Parkinson's disease, 251, 261
- Pasteur, Louis, 15
- Pate v. Robinson, 470
- Pathological gambling disorder, 272–273
- Patients Like Me, 5
- Patient Outcomes Research Team (PORT), 264
- Patterson, Gerald, 382
- Pavlov, Ivan P., 20
- PCP (phencyclidine), 251, 271, 289–291
- PDE-5 (phosphodiesterase type 5) inhibitors, 355
- Pediatric OCD Treatment Study (POTS), 393
- Pedophilic disorder, 358–359
 effects of, 351
 prevalence of, 358
- Peel, Sir Robert, 465
- Peer influences (conduct disorder), 382
- Peer relationships, social anxiety and, 391
- Penile plethysmograph
 defined, 342
 in diagnosis of pedophilic disorder, 358–359
 measuring arousal with, 344
- Pepsi, 321
- Perceived control, 162
- Perception, disturbances of, 428–450
- Percodan, 284, 186
- Perfectionism, 316, 332
- Perinatal factors (in ADHD), 375
- Perphenazine, 263
- Persistent depressive disorder, 115–117, 119–120
- Personal contact, 4
- Personal distress, 6
- Personality
 in analytical psychology, 19
 and anxiety disorders, 167
 and childhood experiences, 20
 and eating disorders, 332
- Personality disorders, 433–461
 and anorexia nervosa, 317
 anxious/fearful cluster of, 434, 454–456
 and bulimia nervosa, 318
 defined, 434
 and dissociative identity disorder, 218
 dramatic/erratic cluster of, 444–453
 in DSM-5-TR, 435–438
 odd/eccentric cluster of, 435–438, 442–444
 and posttraumatic stress disorder, 203
 risk factors for, 440–441
 and somatic symptom and related disorders, 222–224
 treatment of, 457–460
- Personality factors (substance use disorders), 298–299
- Personality inventories, 73–75
- Personality tests, 73–75, 77
 personality inventories, 73–75
- Personality trait domains, 439–440
- Personality trait facets, 439–440
- Personal responsibility, obesity and, 322
- PET (positron emission tomography) scan, 79–80, 422
- p (psychopathology) factor, 66
- PGC (Psychiatric Genomics Consortium), 250
- p-hacking, 110
- Ph.D. degree, 24
- Phelps, Michael, 375
- Phencyclidine. *See* PCP
- Phencyclidine use disorder, 291
- Phenothiazines, 261
- Phenotype, 29
- Phenylketonuria (PKU), 397
- Phobia(s). *See also* Specific phobias
 and classical conditioning, 20–21
 distress/disability from, 7
 empirically supported treatments for, 101
 food, 97–98
 psychological treatment of, 179
- Phoenix House, 307
- Phosphodiesterase type 5 (PDE-5) inhibitors, 355
- Physical conditions, psychological disorders in late life and, 412
- Physical consequences
 of anorexia nervosa, 317
 of binge eating disorder, 322–323
 of bulimia nervosa, 319
 of marijuana use, 282
- Physical effects, of opioids, 286–287
- Physicians
 psychological services referrals from, 233
 psychological treatment for cigarette smoking by, 305
- Physician's certificate, 476
- Physiological arousal, sexual dysfunction and, 350–353
- Physiological component of emotion, 45
- Pica, 314
- Pick's disease, 424
- Pinel, Philippe, 12
- Pituitary gland, 38
- PKU (phenylketonuria), 397–398
- Placebo, 103
- Placebo effect, 103
- Plaques, 420–422
- Pleasure, anhedonia and, 241–242
- PMT (parent management training), 382–383
- Poddar, Prosenjit, 478–479
- Point systems, for children with ADHD, 377
- Police, mobile crisis units and, 482
- Polygenic, term, 28
- Polymorphism, 30
- Polypharmacy, 412
- Pornography, 343
- PORT (Patient Outcome Research Team), 264
- Portion size, 321
- Positive emotion, drug use and, 297–298
- Positive reinforcement, 21
- Positive symptoms, 239–241
- Positron emission tomography. *See* PET scan
- Postsynaptic neurons, 34, 126
- Posttraumatic model (of DID), 219–220
- Posttraumatic stress disorder (PTSD), 199–208
 and childhood sexual assault, 351
 in children and adolescents, 386–387, 39–393
 clinical description of, 199–202
 co-diagnoses with, 64, 66
 and dissociative identity disorder, 218
 empirically supported treatments for, 101
 epidemiology of, 199–202
 etiology of, 203–205
 and insanity defense, 467
 treatment of, 206–208
- Potential victims, protection for, 479
- Potential victims yet unknown, 479

- Poverty, 46, 255–256, 285, 380, 447
Powers, Ron, 3
Prediction of dangerousness, 477–478
Predictive power, of research, 86
Prefrontal cortex, 35
 and borderline personality disorder, 450
 and conduct disorder, 381
 development of, 263
 in mood disorders, 128
 and PTSD, 205
 and schizophrenia, 252–253
 and valuing of rewards, 295–296
Prefrontal lobotomy, 16
Pregnancy
 ADHD and smoking during, 376
 alcohol consumption during, 276
 cocaine use during, 289
 intellectual disability and infections during, 398
 schizophrenia and infections during, 254
 weight gain during, 321
Premature (early) ejaculation, 346, 348, 355
Premenstrual dysphoric disorder, 115
Premotor areas, brain, 295
Prenatal factors, in ADHD, 375
Prepared learning, 171
Preparing for the Drug Free Years, program, 311
Preregistration, hypothesis, 110
Prescription medication, illicit, 284–286. *See also* Medication(s)
Presidents, adaptive narcissism of, 452
Prevalence, 93
Preventive detention, 476–477
Preventive interventions (eating disorders), 337
Primary care interventions (somatic symptom disorders), 233
Prison inmates, 445
Prisons, 13, 482
Privileged communication, 478, 487
Pro-ana websites, 329
Probands, 94
Problem-solving deficits, suicide and, 148
Procedural memory, 215
Prodrome, 246
Pro-eating disorder websites, 329
Pro-inflammatory cytokines, 38, 129
Project EX, 305
Projection, 18
Projective test, 73
Prolonged trauma, PTSD and, 202
Pro-mia websites, 329
Pronoun reversal, 402
Proof, standards of, 466
Property, protection of, 479
Prospective studies (schizophrenia), 258
Prozac. *See* Fluoxetine
Pruning, 36, 254, 405
Psychiatric Genomics Consortium (PGC), 250
Psychiatric hospitals, need for, 481–482
Psychiatric nurses, 24
Psychiatrists, 25
Psychoactive medications, 22–23, 39, 388
Psychoanalysis (psychoanalytic therapy), 17–20
Psychodynamic theories, 20, 215, 232, 452, 457
Psychodynamic therapies/treatment
 for anorexia nervosa, 334–335
 for dissociative identity disorder, 222
 for personality disorders, 457
Psychoeducation, 5
Psychoeducational approaches, 48
 for bipolar disorder, 140
 for childhood anxiety, 393–394
 for dissociative identity disorder, 222
 for eating disorder prevention, 337
 for schizophrenia, 266
 for sexual dysfunction, 354
Psychological approach to psychological disorders, 16–22
 analytical psychology, 19
 behaviorism, 20–22
 cathartic method, 17
 cognition in, 22
 defense mechanisms, 18
 individual psychology, 19
 mesmerism and hypnosis, 16–17
 psychoanalysis, 17–19
 structure of the mind, 18
Psychological assessment, 70–78
 behavior, direct observation of, 76–77
 clinical interviews, 70–73
 cognitive tests, 75–76
 experience sampling, 77
 intelligence tests, 75–76
 methods, 78
 neuropsychological tests, 75–76
 personality tests, 73–75
 self-report questionnaires, 77–77
 of stress, 72–73
Psychological disorders. *See also specific disorders*
 civil rights of people with, 479–483
 and crime, 464
 defined, 2, 6–7
 and disability, 8
 and dysfunction, 7
 and homelessness, 480
 insanity vs., 467
 international prevalence of, 62
 in late life, 414–416
 living conditions of people with, 22–23
 marital distress rates and missed workdays for people with, 68
 and personal distress, 7
 stigma associated with, 2–6
 and suicide, 147–149
 and violation of social norms, 8
 violence linked to, 476–477
Psychological distress, 154
Psychological effects
 of marijuana, 281–282
 of opioids, 286–287
Psychological influences
 in ADHD, 377
 in conduct disorder, 381–382
 in mood disorders, 130–133
 in paraphilic disorders, 362, 364
 in schizophrenia, 255–258
 in sexual functioning, 350–353
 in substance use disorders, 296–299
 and suicide, 148
psychological factors affecting other medical conditions, 225
Psychological risk, psychopathy and, 447–448
Psychological stress. *See* Stress
Psychological treatments
 of ADHD, 377
 of anorexia nervosa, 334–335
 for anxiety disorders, 177–180
 of binge eating disorder, 336–337
 of bipolar disorder, 140–141
 of bulimia nervosa, 335–336
 for cigarette smoking, 305
 culture and ethnicity in, 104
 of dementia, 426
 of depression, 137–140
 of drug use disorders, 306–308
 of obsessive-compulsive-related disorders, 196–199
 of schizophrenia, 264–267
 of trauma-related disorders, 206–208
Psychology
 analytical, 19
 individual, 19
 self-, 452
Psychomotor agitation, 116
Psychomotor retardation, 116
Psychopathology, 2
 advancements in, 22–23
 emotion and, 45–46
 estimating prevalence of, 416
 history of, 9–14
 interpersonal factors in, 47–50
 research designs in, 87–98
 sociocultural factors in, 46–47
Psychopathology (p) factor, 66
Psychopathy, 445–448
 clinical descriptions of, 445–446
 etiology of, 446–448
 media images of, 446
Psychopathy Checklist–Revised (PCL-R), 445–446
Psychophysiological assessment, 79, 81
Psychosocial treatments (schizophrenia), 264–267
Psychotherapeutics, 271, 280
Psychotherapy, 19, 23. *See also* Psychological treatments; *specific disorders*
 for dementia, 426–447
 for dissociative identity disorder, 222
 for personality disorders, 457
Psychotic disorders, 111. *See also* Schizophrenia
Psychoticism, 439
Psy.D. degree, 24
PTSD. *See* Posttraumatic stress disorder
Public, protecting, 366
Publication bias 109–111
Public figures, diagnosing, 485
Puerto Rico, 8, 202
Purging, 318
Pussin, Jean-Baptiste, 12
- Q**
Questionable research practices, 109
Quetiapine, 262
- R**
RAISE (Recovery After and Initial Schizophrenia Episode) Early Treatment Program, 267
Random assignment, 88, 95–96, 100
Randomized controlled trials (RCTs), 100, 105, 364
Random variation, 91
Rape, 363
Rationalization, 18
Rayner, Rosalie, 21, 170
RCTs. *See* Randomized controlled trials
RDoC (research domain criteria), 66
Reaction formation, 18
Reactivity, 201
Reagan, Ronald, 420, 465–466
Rebirthing, 102
Recessive-gene diseases, 397–398
Recovered memories, 216–217
Recovered-memory techniques, 102
Recovery After and Initial Schizophrenia Episode (RAISE) Early Treatment Program, 267
Referrals, from physicians, 233
Regression, 18
Reinforcement, 21, 220
Rejection, by peers, 382
Relapse, by people with schizophrenia, 256–258
Relapse prevention, 302, 365
Relational self, 19
Relationship distress and problems
 empirically supported treatments for, 101
 and personality disorders, 434
 and sexual dysfunctions, 346, 351–352, 354
Relaxation, 174
Relaxation training, 180
Reliability, 55–56, 68
Repetitive acts, 402–403
Replication, 108–110
Reporting bias, 416
Representative samples, 88, 93
Repression, 18, 216–217, 222
Research, restraints on, 484–486

- Research domain criteria (RDoC), 66
- Research methods, 86–113
 analogues in, 106–108
 case studies, 92–93
 correlational method, 88–95
 experiments, 95–106
 for integrating study findings, 108–111
 in psychopathology, 87–98
 in study of aging, 412–414
 theory and hypotheses, 87
 treatment outcome research, 100–105
- Residential treatments, 267, 307, 398
- Resistance, 72
- Resolution phase (sexual response), 344
- Reston, Ana Carolina, 317
- Restraints on research, 484–486
- Reuptake, 34
- Reversal (ABAB) design, 98
- Rewards, immediate vs. delayed, 295–296
- Reward sensitivity, 135
- Reward system, 126, 128, 135, 321
- Ricci, Christina, 331
- Right to refuse treatment, 481
- Right to treatment, 480–481
- Rinaldi, Gina, 211
- Risk calculator (schizophrenia), 259
- Risk factors
 for anxiety disorders, 163–169
 in eating disorder prevention, 337
 for personality disorders, 440–441
- Risperidone (Risperdal), 262–263, 407, 458
- Ritalin, 376
- Rituals and ritualistic acts, 402–403
- Rivastigmine (Exelon), 425
- RNA, 30
- Role disputes, 49
- Role-playing, of DID symptoms, 221
- Role transitions, 49
- Rorschach Inkblot Test, 74
- Routh, Eddie Ray, 467
- Routines, teaching children, 399
- rTMS (Transcranial magnetic stimulation), 143
- Rubens, Peter Paul, 328
- Rumination, 133
- Rumination disorders, 314
- Rumination theory, 133
- Rush, Benjamin, 12
- Russia, 20, 305
- S**
- Sacks, Oliver, 404
- SAD (seasonal affective disorder), 118–120
- Safety behaviors, 168, 171, 179, 231, 234
- Saks, Elyn, 265, 473
- Sambians, 340
- SAMHSA (Substance Abuse and Mental Health Services Administration), 274, 280
- Samples, 103–104
- Satcher, David, 3
- Satiation, 365
- SB5 (Stanford–Binet, 5th edition), 75
- Scared Straight, 102
- Schema, 41–42
- Schizoaffective disorder, 244
- Schizoid personality disorder, 442
 in Alternative DSM-5-TR model, 438
 inter-rater reliability for, 437
 key features of, 435
 prevalence of, 436
- Schizophrenia, 238–269
 and brain, 253–54
 clinical descriptions of, 239–246
 cultural bias in diagnosis of, 82–83
 defined, 239
 developmental factors in, 258–259
 disorganized symptoms of, 242–244
 electroconvulsive therapy for, 16
 emotional expression with, 45–46
 empirically supported treatments for, 101
 environmental factors and, 254–255
 etiology of, 246–259
 family therapy in treatment for, 48
 functional connectivity with, 36
 genetic factors in, 247–251
 heritability of, 15–16
 history of concept of, 244
 and informed consent, 486
 medication-based treatment of, 260–264
 misdiagnosis of, 65
 negative symptoms of, 241–242
 and neurotransmitters, 251–253
 in older adults, 415
 positive symptoms of, 240–241
 psychoactive medications for, 23
 psychological influences on, 255–258
 psychological treatments of, 264–267
 researching, 92
 and schizotypal personality disorder, 443
 sociocultural factors in, 46–47
 treatment of, 260–267
- Schizophrenia spectrum disorders, 244, 476
- Schizophrenia Working Group, 125, 250
- Schizophreniform disorder, 244
- Schizophrenogenic mother, 256
- Schizotypal personality disorder, 442–444
 comorbidities for, 438
 heritability of, 441
 inter-rater reliability for, 437
 key features of, 435
 prevalence of, 436
 test–retest stability for, 437
 treatment of, 458
- School interventions (specific learning disorders), 398–399
- Schumann, Robert, 124
- SCID (Structured Clinical interview), 70–72
- Science, 87
- Sean Costello Memorial Fund, 124
- Seasonal affective disorder (SAD), 118–119
- Second-generation antipsychotic drugs, 262–264
- Secondhand smoke, 278–279
- Selective mortality, 413, 416
- Selective mutism, 391
- Selective prevention programs for depression, 390
- Selective serotonin reuptake inhibitors (SSRIs), 141
 and mood disorders, 141–142
 and obsessive-compulsive disorder, 196
 and PTSD, 206
 and sexual function, 350
 for treatment of anxiety and depression, 65
 for treatment of anxiety disorders, 180–181
 for treatment of paraphilic disorders, 365
- Self, sense of, 449
- Self-blame, 352
- Self-critical beliefs, 146
- Self-esteem, 327–328, 452–453
- Self-evaluation, social anxiety disorder and, 172
- Self-help groups, 302
- Self-help residential homes, 307–308
- Self-image, 328–329
- Self-monitoring, 77
- Self-objectification, 330
- Self-overestimation of social performance, by children with ADHD, 372
- Self-perceptions, negative, 412
- Self-psychology, 452
- Self-reports, of sexual dysfunction symptoms, 32–333
- Self-stimulatory activities, 403
- Selye, Hans, 72
- Sensate focus, 354–355
- Separation anxiety disorder, 385, 391, 393
- Sequenced Treatment Alternatives to Relieve Depression (STAR-D) trial, 142
- Serotonin, 34
 and alcohol, 274
 and anxiety disorders, 167
 and eating disorders, 325–326
 and Ecstasy, 290–291
 and hallucinogens, 289–291
 and methamphetamine use, 288–289
 and mood disorders, 125–126
 and schizophrenia, 251–252
 and suicide, 147
- Serotonin–norepinephrine reuptake inhibitors (SNRIs), 141
 and mood disorders, 141–142
 for treatment of anxiety disorders, 181
- Serotonin transporter gene, 133–134, 386–387
- Sertraline (Zoloft), 393
- SERT transporter, 291
- SES (socioeconomic status), 29
- Sex drive, low, 346
- Sex offenders, 365–366
- Sex-reassignment surgery, 342
- Sexual abuse, 351. *See also* Childhood sexual abuse (CSA)
- Sexual anatomy, 343
- Sexual desire disorders, 345–346
- Sexual disorders, 335–368
 paraphilic disorders, 356–366
 sexual dysfunctions, 344–356
 and sexual norms, 340–344
- Sexual dysfunctions, 344–356
 and childhood sexual assault, 369
 clinical descriptions of, 344–349
 DSM-5-TR criteria for, 345
 empirically supported treatments for, 101
 etiology of, 350–353
 orgasmic disorders, 347–348
 prevalence of, 345
 sexual interest, desire, and arousal disorders, 346–347
 sexual pain disorders, 349
 treatments of, 353–356
- Sexual impulse control strategies, 365
- Sexual interest, 346–347
- Sexual interest, desire, and arousal disorders, 344–348
- Sexuality, 340, 342–344
- Sexual masochism disorder, 357–358, 360
- Sexual norms, 340–344
- Sexual pain disorders, 349, 355
- Sexual performance, cognitions about, 350–352
- Sexual sadism disorder, 357–358, 360
- Shame, body, 330
- Shared environment, 28
- Shenjing shuairuo*, 62–63
- “shoulder,” 288
- Sickness behavior, 129
- Sidibe, Gabourey, 330
- Significance
 clinical, 90–92
 statistical, 90–92, 111, 293
- Sildenafil (Viagra), 355–356
- Simple phobia, 101
- Sinatra, Frank, 124
- Single-case experimental design, 88, 96–98
- Single nucleotide polymorphisms (SNPs), 31–32, 125, 250, 293, 405
- Skin conductance tests, 381, 447
- Skinner, B. F., 21
- SLC6A3 gene, 293
- Sleep
 and aging, 412
 disturbances in, 213, 417, 429
 and mania, 135
- Smoke-free environments, 279
- Smoking. *See* Cigarette smoking
- Smoking-cessation programs, 297, 305–306
- SNPs. *See* Single nucleotide polymorphisms

- SNRIs (serotonin-norepinephrine reuptake inhibitors), 141
- Sobell, Linda, 304
- Sobell, Mark, 304
- Social anxiety, 391–393, 403
- Social anxiety disorder(s), 63, 155.
See also Social phobia
 and avoidant personality disorder, 454
 in children and adolescents, 385, 392–393
 clinical description of, 158–159
 etiology of, 171–173
 prevalence of, 156
 psychological treatment of, 179
- Social-cognitive perspective (aggressive behavior), 381
- Social (pragmatic) communication disorder, 395
- Social cues, attention to, 172
- Social deficits, 49
- Social disturbances (with ASD), 400–402
- Social influences (antisocial personality disorder), 446–447
 on anxiety disorders, 162–163
 on bipolar disorders, 134–135
 on body dysmorphic disorder, 188–189
 on conduct disorder, 380–381
 in conversion disorder, 232
 in depression, 129–130
 in quitting smoking, 304–305
 in sexual functioning, 351–352
 in substance use, 299
 and suicide, 147
- Social information processing, antisocial behavior and, 382
- Social networks, 299–300
 expansion of, 266
- Social norms, violations of, 8
- Social performance, self-overestimation of, 372
- Social phobia, 101, 415. *See also* Social anxiety disorder(s)
- Social relationships, frontotemporal dementia and, 423–424
- Social selectivity, 411
- Social skills, of children with ADHD, 372
- Social skills training, 101, 264, 267
- Social support, 130, 205
- Social workers, 25
- Sociocognitive model (of DID), 219–221
- Sociocultural influences
 in eating disorders, 328–329
 in psychopathology, 46–47
 in schizophrenia, 255–256
 in substance use disorders, 299–300
- Socioeconomic status (SES), 29
- Sodium pentothal, 220
- Soloist, The* (Lopez), 243
- Somatic symptoms, 179, 229–230
- Somatic symptom and related disorders, 211–237
 clinical descriptions of, 222–228
 diagnoses of, 223
 etiology of, 228–232
 in late life, 411
 mechanisms of, 230–231
 treatment of, 233–235
- Somatic symptom disorder, 111, 223
 clinical description of, 224–225
 diagnosis of, 223
 and dissociative identity disorder, 218
 with pain, 235
 treatment of, 233–235
- Somatiform disorder, 223
- Somatosensory cortex, 229
- South Africa, 104
- South Asia, 162
- SP (symbolic play), 407
- Spain, 62, 104, 305
- Specialness, 452
- Specific learning disorder, 394–399
- Specific phobias, 164
 in adolescents, 385–386
 and anorexia nervosa, 317
 and autism spectrum disorder, 403
 clinical description of, 156–157
 etiology of, 170–171
 prevalence of, 93, 16
 psychological treatment of, 179
 types of, 157
- SPECT scan, 80
- Speech, 242–243
- Speech sound disorder, 395
- Spellbound* (film), 214
- Spice, 280
- Squeeze technique, 355
- SSRIs. *See* Selective serotonin reuptake inhibitors
- Stability, of personality disorders, 437
- Stable attributions, 132
- Standardization, 73
- Stanford-Binet, 5th edition (SB5), 75
- Starbucks, 287
- STAR-D (Sequenced Treatment Alternatives to Relieve Depression) trial, 142
- Star Trek* (television series), 404
- Statistical significance, 90–92, 111, 293
- Stereotypes, 75–76, 104–105, 326, 329
- Stereotype threat, 75–76
- Stereotypical behavior, 402–403
- Stereotypic movement disorder, 395
- Sterilization (mentally ill), 15–16
- Stigma, 2–5
 and diagnosis, 69
 of drug and alcohol use disorders, 273
 of eating disorders, 314
 fighting against, 4–5
 of obesity, 322
 and psychological disorders on television, 22
 of somatic symptom and related disorders, 224
- Stimulants (stimulant medications), 287–289
 for ADHD, 39, 376–377
 amphetamines, 288
 caffeine, 287
 for childhood disorders, 388
 cocaine, 289
- Stone, Emma, 159
- STOPP/START system, 412
- Strattera, 376
- Strengthening Families Program, 311
- Stress, 72–73
 and alcohol/nicotine consumption, 297
 and bulimia nervosa/binge eating disorder, 327
 and depersonalization/derealization disorder, 213–214
 and depression, 117–118
 and dissociation, 214
 and dissociative amnesia, 216
 and eating, 321
 history of, 72
 hormones related to. *See* Cortisol
 and immune system functioning, 38
 and schizophrenia, 255
- Striatum, 125–126
- Strong, 365, 5
- Structural connectivity, 36
- Structured Clinical Interview (SCID), 70–72, 78
- Structured interviews, 70–72
- Studies in Hysteria* (Breuer & Freud), 17
- Stuttering, 395
- Styron, William, 115
- Subjective feeling, 45
- Subjective Units of Distress Scale (SUDS), 97
- Sublimation, 18
- Suboxone (buprenorphine), 286, 309
- Substance abuse. *See also* Alcohol abuse; Drug abuse
 and ADHD, 374
 and antisocial personality disorder, 445
 and childhood sexual assault, 351
 and conduct disorder, 378–379
 in late life, 416
 and memory loss, 215
 and posttraumatic stress disorder, 202
 and violence by mentally ill persons, 476
- Substance Abuse and Mental Health Services Administration (SAMHSA), 270, 274, 416
- Substance dependence, 111
- Substance use
 conduct disorder treatments and, 384
 drug use and ADHD medications, 389
 prevalence of drug use, 270–271
 and schizophrenia, 239
- Substance use disorders, 270–312
 alcohol use disorder, 273–276
 and binge eating disorder, 322–323
 and bulimia nervosa, 319
 caffeine, 287
 clinical descriptions of, 273–292
 co-diagnoses with, 66
 in DSM-5-TR, 59, 270–273
 effects of, 273–283, 286–287, 289–292
 etiology of, 292–300
 genetic influences, 292–293
 hallucinogens, ecstasy, and PCP, 289–291
 international prevalence of, 62
 living conditions for people with, 22–23
 marijuana, 280–283
 neurobiological influences, 293–296
 nitrous oxide, 291
 and obsessive-compulsive related disorders, 192
 opioids, 284–287
 prevalence of, 270–274, 277, 284–296, 288
 prevention of, 310–311
 psychological influences, 296–299
 sociocultural influences, 299–300
 and somatic symptom and related disorders, 229
 stimulants, 287–289
 on television shows, 22–23
 tobacco use disorder, 277–280
 treatment of, 301–310
 “Substantial capacity,” 465
- SUDS (Subjective Units of Distress Scale), 97
- Suicidal behavior
 and antidepressants, 389–390
 and borderline personality disorder, 448–449
 and dialectical behavior therapy, 95
 and schizophrenia, 239
- Suicidal ideation, 148–149
- Suicidality, treatment for, 148–150
- Suicide
 and ADHD, 373
 and anorexia nervosa, 317
 and bipolar disorders, 123
 and bulimia nervosa, 319
 epidemiology of, 145–147
 and mood disorders, 144–150
 and nonsuicidal self-injury, 146
 preventing, 148–150
 risk factors for, 147–148
- Suicide attempts, 145–147
- Superego, 18
- Supernatural, as cause of psychopathology, 9–11
- Support groups, 5
- Surgeon General of the United States, 3, 263, 277–279, 302, 310
- Surveys, of sexual behavior, 345
- Susto*, 162
- Sybil, 226
- Sybil* (Schreiber), 226
- Symbolic play (SP), 407
- Sympathetic nervous system, 34
- Symptoms, 59–60
- Synapses, 34–35
- Syndrome, 58
- Synthesis, 459
- Synthetic marijuana, 280
- Syphilis, 14–15
- Systematic desensitization, 101

- T**
- Tactile Performance Test, 76
- Tadalafil (Cialis), 355
- TADS (Treatment of Adolescents with Depression Study), 387–389
- Taijin kyofusho*, 62–63, 162
- Tarasoff, Tatiana (Tanya), 478–479
- Tarasoff v. Regents of the University of California*, 478–479
- Tardive dyskinesia, 261
- Tarloff, David, 464
- TAT (Thematic Apperception Test), 74
- Tchaikovsky, Piotr Ilych, 123
- Teacher training approaches (conduct disorder), 383
- Teenagers. *See* Adolescents
- Television shows, people with psychological disorders on, 22–23
- Temporal cortex, 253
- Temporal lobes, 402
- Tension, effects of alcohol and nicotine on, 296
- Test anxiety, 154
- Testosterone, 350
- Test–retest reliability, 55. *See also* Reliability
- Texas, 467, 471, 474
- Thailand, 305, 370–371
- THC (delta-9-tetrahydrocannabinol), 281
- Thematic Apperception Test (TAT), 74
- Theory, 87
- Theory of mind, 402
- Therapeutic effect, of marijuana, 282
- Therapists and recovered memories, 216–217
- reinforcement of DID symptoms by, 221
- Thesis, 459
- Thimerosal, 389
- Thinking in Pictures* (film), 404
- Thinness, 316, 328–332
- Third-variable problem, 88, 92
- Thorazine, 261–262
- Thorndike, Edward, 21
- Thought-action fusion, 193
- Thought broadcasting, 240
- Thought disorders, 439
- Thought insertion, 240
- Thought suppression, 193
- Threat(s)
- anxiety disorders and attention to, 165, 168–169
- psychopathy and response to, 447–448
- Three Faces of Eve*, *The* (Thigpen & Cleckley), 218
- Timeline Follow Back (TLFB)
- interview, 303
- Time-of-measurement effects, 413
- Time-out, 41
- TLFB (Timeline Follow Back)
- interview, 303
- Tobacco Education Media Campaign, 278
- Tobacco use disorder, 277–280
- and e-cigarettes, 279–280
- genetic influences, 292–293
- health consequences of secondhand smoke, 278–279
- prevalence and health consequences of smoking, 277–278
- treatments for, 304
- Tolerance, 272–273, 282, 287
- Torture, 484
- Touched with Fire* (Jamison), 123
- Tourette's disorder, 395
- Toxic effect model (substance dependence), 293
- Toxins, hyperactivity and, 375. *See also* Environment and environmental factors
- Toxoplasma gondii, 254
- Training, 4–5, 83–84
- Tramadol, 286
- Transcranial magnetic stimulation (rTMS), 143
- Transcription, 30
- Transference, 19
- Transference-focused therapy, 459
- Transgender individuals, 341–342
- Transinstitutionalization, 481
- Transvestic disorder, 357
- Trauma, 170, 199, 201, 203–204
- Trauma-related disorders, 199–210
- anxiety disorders and, 155
- clinical descriptions of, 199–203
- epidemiology of, 199–203
- etiology of, 203–205
- treatment of, 206–208
- Treatment(s). *See also* Psychotherapy; *under specific headings, e.g.*–Eating disorders
- empirically supported, 101
- neuroscience approaches to, 39
- right to, 480–481
- right to refuse, 482
- Treatment Advocacy Center, 13, 482
- Treatment-as-usual control group, 103
- Treatment manuals, 102
- Treatment of Adolescents with Depression Study (TADS), 387–389
- Treatment outcome research, 100–106
- assessment in, 105
- control groups in, 102–103
- defined, 100
- dissemination of findings from, 105
- effect sizes in, 111
- samples in, 103–104
- treatment condition in, 102
- Tremors, 232
- Trial, competency to stand, 469–472
- Tricyclic antidepressants, 141
- Trisomy 21, 397
- truth campaign, 311
- Truth Initiative, 310
- Tunnel vision, 226
- “Tweaking,” 288
- 12 steps (of Alcoholics Anonymous), 302
- Twin method, 95
- Twin studies
- of ADHD, 375
- of anxiety disorders, 166, 175
- of autism spectrum disorder, 405
- of conduct disorder, 380–381
- of depression, 131
- of eating disorders, 324
- of pedophilic disorder, 351
- of personality disorders, 450
- of schizophrenia, 247–249
- of substance use disorders, 292–293
- of suicide risk, 147
- Two-factor model of conditioning, 164–165, 171
- Tylox, 284
- U**
- UCR (unconditioned response), 20. *See also* Classical conditioning
- UCS (unconditioned stimulus), 20. *See also* Classical conditioning
- Ukraine, 104
- Uncertainty, intolerance for, 168
- Unconditioned response (UCR), 20. *See also* Classical conditioning
- Unconditioned stimulus (UCS), 20. *See also* Classical conditioning
- Unconscious, 18–20, 42–43, 232
- Unemotional traits, 378, 380–381
- Unexplained blindness, 232
- Unique environment, 28
- United Kingdom, 58, 265, 276, 336, 388–389, 393. *See also* England; Great Britain
- United States
- alcohol consumption, 93, 104
- antidepressants in, 136, 387–389
- anxiety disorders, 155
- autism spectrum disorders, 389
- binge eating disorder in, 319
- civil liberties of sex offenders, 366
- drug use, 271
- eating disorders in, 330
- expectations about sex drive, 346
- ideal affect, 46
- internalizing and externalizing behavior problems, 370–371
- lifetime prevalence rates of diagnoses in, 93
- methamphetamine use, 271
- moral treatment in, 12–13
- obesity in, 320
- older adult population of, 410–411
- opioid addiction, 285
- panic attacks, 159
- people seeking treatment, 105
- preoccupation with food in, 313
- prevalence of PTSD in, 202
- rape in, 363
- rates of psychological disorders, 61–63
- residential treatment for schizophrenia in, 267
- sexual norms, 342
- smoking cessation programs in, 295
- substance use disorders, 274
- suicide and suicide attempt rates, 146–147
- tobacco use in, 277
- U.S. Department of Agriculture, 321
- U.S. Department of Health, Education, and Welfare, 485
- U.S. Department of Health and Human Services, 485
- U.S. Supreme Court, 16, 366, 466, 468, 470, 472, 474–475, 478–481
- Universal prevention programs for depression, 390
- Unresolved grief, 49
- “Unspecified” category, DSM, 63
- Unstructured clinical interviews, 436
- Uppgivenhetssyndrom*, 63
- Upp, Hannah, 215
- Urbanicity, 255–256
- Utah, 279, 282, 468
- V**
- Vaccines, 389
- Vaginal plethysmograph, 342
- Vaginismus, 349
- Validity, 56–57
- construct, 56
- content, 56
- criterion, 56
- in diagnosis and assessment, 56–57
- of DSM diagnostic categories, 68
- external, 96
- internal, 96
- Validity scales, 74
- VAMC (Veterans Affairs Medical Center), 207
- Vaping, 279–280
- Vardenafil (Levitra), 355
- Varenicline (Chantix), 306
- Variables
- correlation of, 90
- dependent, 88, 95
- independent, 88, 95
- third-variable problem, 88, 92
- Vascular dementia, 420, 424
- Ventral striatum, 325, 280
- Ventricles, 35, 252
- Veterans Administration, 8, 13, 135, 137
- Veterans Affairs Medical Center (VAMC), 207
- Viagra (sildenafil), 335
- Vicodin, 284
- Vietnam War, 200–201
- Violence, 363, 446, 476–477
- Virginia, 475
- Virtual reality (VR) technology, 178, 207
- Vocational rehabilitation, 267
- Voucher treatments, 307
- Voyeuristic disorder, 357, 359, 362

VR (Virtual reality) technology,
178, 207
Vulnerability model of substance
dependence, 293

W

WAIS-IV (Wechsler Adult
Intelligence Scale, 4th
edition), 75
Wales, 299
Walker, Elaine, 258
Walker, Scott, 3
Wanting, neurobiology of,
294, 325
Washington, D.C., 465–466
Watson, John B., 21
Wechsler Adult Intelligence Scale,
4th edition (WAIS-IV), 75
Wechsler Intelligence Scale
for Children, 5th edition
(WISC-V), 75
Wechsler Preschool and Primary
Scale of Intelligence, 4th
edition (WPPSI-IV), 75
Weight, stigma about,
313–314
Weight gain, as side effect, 263
Wellbutrin (bupropion), 306
Were (Yoruba concept), 46
Wernicke's area, 241
Western cultures
body dysmorphic disorder in,
189
ideal affect in, 46
self-reports of sexual
dysfunction symptoms in,
358
sexual norms in, 340
thinness and eating disorders
in, 330
Whippets, 291
Whites, 47, 103, 156, 229, 263,
274, 277, 285, 290, 300,
309, 331–332, 424. *See also*
Anglo Americans; European
Americans
White, Eve, 218
White matter, 35
WHO (World Health Organization),
58, 320
Williams, Ricky, 181
Williams, Robin, 147
Wind attacks, 62
Wine, 275

Winter blues (seasonal affective
disorder), 118–119
WISC-V (Wechsler Intelligence
Scale for Children, 5th
edition), 75
Withdrawal, 272
alcohol, 273–274, 302
avoiding symptoms of,
293–294
caffeine, 287
and drug use disorders, 306
marijuana, 282–283
opioid, 286–287
Wolf of Wall Street, The (film),
446
Women, 411. *See also* Gender
Woolf, Virginia, 148
World Health Organization (WHO),
58, 320
World Mental Health Survey, 93,
104, 123, 202–203
World War II, 204, 485
Worry(-ies), 160, 180, 388
WPPSI-IV (Wechsler Preschool
and Primary Scale of
Intelligence, 4th edition), 75
Wright, Frank Lloyd, 451

Writings, recovered memories
from, 216–217
Wyatt v. Stickney, 480

X

Xanax (alprazolam), 39

Y

Yates, Andrea, 470
Yoruba, 46
Young adults. *See also* College
students
advertising and substance use
by, 300
drug use trends for, 280
smoking cessation programs
for, 305
Young children, PTSD symptoms
of, 391

Z

Zeta-Jones, Catherine, 122
Zimbabwe, 299, 330
Ziprasidone, 262
Zoloft (sertraline), 141, 393
Zydone, 284
Zyprexa. *See* Olanzapine

